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Background Cardiovascular Magnetic Resonance (CMR) plays an important 
role in out of hospital cardiac arrest survivors, not only as a diagnostic tool, but 
also as a guide to clinical decision-making and to patients’ management: CMR 
has shown to have a clinical impact in a considerable proportion of patients 
surviving both tachy-arrhythmic cardiac arrest and pulseless electrical activity. 
There is also growing evidence of the predictive role of CMR, especially in the 
setting of ventricular arrhythmias. In patients surviving ventricular fibrillation 
(VF) cardiac arrest, recurrence of Major Cardiovascular Adverse Events 
(MACE) is not rare. We sought to identify CMR-derived structural and functional 
myocardial predictors of MACE recurrence in VF cardiac arrest survivors.  
Material and Methods We retrospectively analysed our CMR registry to enrol 
VF cardiac arrest survivors. All patients underwent a 1.5 T CMR, 
comprehensive of long and short-axis cine and late gadolinium enhancement 
(LGE) sequences. LGE was quantified with semi-automated software using the 
full width at half maximum method (cvi42, Circle Cardiovascular Imaging). 
Tissue tracking analysis software was used to assess myocardial deformation 
(cvi42, Circle Cardiovascular Imaging). Primary end-points were all-cause 
mortality and appropriate ICD discharge/anti-tachycardia pacing. 
Results We enrolled 121 patients [82% male, 62 years (IQR 53-70)]. CMR was 
performed within 13 days (IQR 6-42) from VF arrest. Left ventricular (LV) 
systolic function was mildly impaired [LVEF 54 (41-64)%], right ventricular 
systolic function was preserved [RVEF 60 (53-65)%]. LGE was found in 71% of 
patients, median mass was 6.2 (0-15)% of the left ventricle. Myocardial 
deformation was overall impaired [global longitudinal strain, -15.5 (-18.9- -
12.3)%; global radial strain, 34.2 (25.2-45.2)%; global circumferential strain, -
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15.5 (-20.3- -11.9)%]. There was a significant correlation between LGE mass 
and myocardial deformation (p<0.001). On CMR, 75 patients (62%) were 
diagnosed with ischemic heart disease (IHD) and 20 (17%) with non-ischemic 
heart disease (NIHD); a structural normal heart was found in 26 (21%). Fifty-two 
per cent of patients were implanted with an ICD. After a median follow-up of 24 
months (IQR 6-41), 22 patients (18%) were lost to follow-up. Primary end-point 
was met in 24 patients (14 deaths, 10 appropriate ICD discharge). LVEF did not 
differ between patients with and without end-point (p=0.128), while RVEF was 
significantly lower in those meeting the end-point (58% vs 61%, p=0.03). LGE 
prevalence did not differ between patients with and without end-point (p=0.075) 
but its extent was significantly greater in patients experiencing adverse events 
(LGE mass 8.6% of LV vs 4.1%, p=0.02). Myocardial deformation did not differ 
between patients with and without end-point. Patients with LGE mass >4.3% 
represented a subgroup at a higher risk of adverse events (p=0.0048).  
Conclusions In a population of VF cardiac arrest survivors, CMR was able to 
identify a pathological substrate of the cardiac arrest in 79% of cases. While 
CMR-derived myocardial deformation assessment was not able to differentiate 
patients experiencing adverse events from those event-free, an LGE mass 
>4.3% of LV myocardium identified a subgroup of patients at a higher risk of 
developing adverse events. Further studies, in larger populations, are warranted 
to expand the findings on the role of CMR as risk stratification tool in this group 
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Chapter 1. Non-traumatic out of hospital cardiac arrest 
 
Non-traumatic out of hospital cardiac arrest (OHCA) is the leading cause of 
death worldwide (1), being responsible for more than 350,000 deaths in the 
United States of America, only in 2014 (2). The real incidence of OHCA is 
difficult to establish, as OHCA definition, management and outcome recording 
vary widely across different countries’ registries (3)(4)(5)(6). In 1990 a group of 
experts provided a unified classification of OHCA, called the “Utstein style”, 
which aimed at providing criteria for the definition of OHCA and its outcome (3) 
(7); these criteria, which have been modified through the years, in order to 
make it easier to report OHCA events, were finally approved in 2012 (6). Based 
on these “revised Utstein style” criteria, a recent multi-centre one-month study 
conducted in Europe (EuReCa ONE) showed an incidence rate of 84 per 
100.000 (8). Incidence of OHCA increases with age, and is more frequently 
associated with male gender and background of coronary artery disease (CAD) 
(7)(9). Although a positive history of CAD is found in 80% of cases (10), OHCA 
is the first manifestation of an underlying cardiac disease in up to 20-40% of 
cases (9), even more so now that incidence of CAD has progressively 
decreased; this led to a change in the at-risk population, which is now mainly 
represented by patients with no pre-existing cardiac diseases, and that would 
not meet indications for primary prevention implantable cardiac defibrillator 
(ICD) implantation (11). The incidence of OHCA varies considerably when 
considering different risk sub-groups: patients with high coronary risk profile 
have 0.1–0.2 per 1000 per year incidence of sudden cardiac death (SCD), 
those with prior coronary event have 0.5 per 1000 per year incidence, patients 
with heart failure and reduced ejection fraction have 1.5 per 1000 per year 
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incidence, while patients surviving a cardiac arrest have an incidence of 2.5 per 
1000 per year (12).  A progressive decrease in the incidence of shockable 
rhythms (ventricular fibrillation (VF)/ventricular tachycardia (VT)) has also been 
recently reported (8)(11)(13), mainly as a consequence of increased use of 
beta-blockers and of ICDs. However, survival rates have not improved over the 
years and remain still quite unsatisfactory, with an overall estimated rate of 10% 
(8)(14). Effective cardio-pulmonary resuscitation (CPR) and early defibrillation 
have been shown to be the most important rings of the chain of survival, playing 
a pivotal role in increasing survival rate: one of the most successful public 
health strategies has been indeed the training of laypersons to perform CPR 




Almost half of all sudden deaths have a cardiovascular origin (14)(16), 
attributable to underlying CAD or ischemic heart disease (IHD) in up to 80% of 
cases (14)(17), and to non-ischemic heart disease (NIHD) in 15% of cases (18). 
An underlying cardiomyopathy is usually identified in 90% of patients surviving 
OHCA, but no cause is clearly identifiable in approximately 5-10% of cases 
(19)(20).  
 
1.1.1 Ischemic Heart Disease  
Despite the progressive decrease in CAD prevalence (1)(9)(15), IHD still 
represents the leading cause of death worldwide, and CAD alone explains up to 
50% of all deaths (17). When looking at how OHCA manifests in this cohort of 
patients, it appears that cardiac arrest is the first manifestation in a considerable 
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proportion of patients (40-60%)(1), frequently occurring in those with known 
CAD but considered to be at low risk for major cardiovascular events (MACE), 
while it affects less than 25% of high-risk patients (prior myocardial infarction, 
MI, prior ventricular arrhythmias or history of heart failure); the remaining cases 
are represented by acute coronary syndromes (ACS) (10)(17), which explain 
approximately 50% of sudden ischemic deaths (21).  
A tachyarrhythmia (VT/VF) is the most common presenting rhythm in this group 
of patients, and is based on two major mechanisms: 1) acute ischemia, both 
transient or prolonged, secondary to abrupt plaque rupture determining <50% 
lumen patency, and 2) re-entrant electrical circuit in the context of myocardial 
scar (17)(22); recent studies performed with Cardiovascular Magnetic 
Resonance (CMR) imaging have shown that these two entities, acute ischemia 
and myocardial scar, can co-exist as causes of OHCA (23). The different 
pathogenic mechanisms explain the at-risk populations features: on one hand, 
patients with acute ischemia usually have neither previous history of CAD nor 
symptoms preceding the index event, preserved left ventricular ejection fraction 
(LVEF) and a higher incidence of acute coronary thrombosis in a single vessel; 
on the other hand, patients with scar-related OHCA tend to have a background 
of MI, impaired left ventricular ejection fraction (LVEF) and multi-vessel disease 
on coronary angiogram.  
Cardiac arrest is four to six times more frequent in patients who had a 
myocardial infarction, with an annual incidence of 2-4%, and the risk is 
significantly higher in the first 30 days post-MI and exponentially decreases over 




1.1.2 Non-ischemic heart disease 
Non-ischemic heart disease (NIHD) is responsible of OHCA in approximately 
15-20% of cases (18)(19)(24). NIHD patients experiencing OHCA are usually 
young (≤35 years), fit, and otherwise well; the impact of life-years lost due to 
SCD in the young is greater than those due to cancer (25), with an SCD 
incidence in the 1-40 years population of 1.3-8.5 per 100,000 person-years.  
The mechanism underlying OHCA in this group of patients is either genetically 
determined or secondary to the presence of myocardial scar. Most data on SCD 
occurring in this group of patients came from studies on SCD among young 
competitive athletes (≤35 years) (26)(27)(28): a large population study 
conducted in the Veneto region, in Italy, found a considerable prevalence, of 
approximately 2.3 per 100,000 athletes-year (26). Among non-ischemic 
cardiomyopathies, hypertrophic cardiomyopathy (HCM) accounts for one third 
of all OHCA cases (29)(30), followed by arrhythmogenic right ventricular 
cardiomyopathy (ARVC) and anomalous coronary arteries, that account for 15% 
of cases (24), while all the remaining cardiomyopathies (dilated 
cardiomyopathy, DCM, myocarditis, sarcoidosis) account for approximately 6% 
of cases (31)(32)(33). Anomalous coronary arteries, though found in only 1% of 
the population, are the commonest congenital heart disease in grown-up 
cardiac arrest survivors and represent the second most common cause of SCD 
in the young; cardiac arrest is secondary to haemodynamic instability due to a 
“malignant” artery course (i.e. inter-arterial course between the aortic root and 
the pulmonary artery) (24). Myocarditis accounts for approximately 5-10% of all 
cases of cardiac arrest and is generally secondary to fatal ventricular 
arrhythmias precipitated by inflammatory myocardial foci that do not alter LVEF 
or resting electrocardiogram (18)(25). Despite an overall annual risk of death of 
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0.1% in this young population, cardiomyopathies, such as HCM, DCM and 
ARVC, imply an annual risk of death of 2-4% (34).  
 
1.1.3 Idiopathic ventricular fibrillation 
The absence of an underlying cause of a tachyarrhythmia-induced OHCA, 
which is referred to as idiopathic ventricular fibrillation (IVF), is encountered in 
5-10% of patients, and represents a great challenge, not only from a diagnostic 
perspective, but mainly from a prognostic one, as adverse arrhythmic events 
can recur in up to 30% of cases (20). IVF diagnosis is only possible once an 
extensive work-up has excluded all the possible structural heart diseases, both 
ischemic and non-ischemic, hence it is quite challenging, and that is why its 
incidence and pathogenesis are not jet completely understood. In order to 
improve the understanding and characterisation of this entity, two international 
registries, based in the United States (Idiopathic Ventricular Fibrillation Registry 
of the United States, IVF-US) and Europe (Unexplained Cardiac Arrest Registry 
in Europe, UCARE), respectively, were started in the 90’s and are still on going.  
Recent studies showed that up to 30% of unexplained OHCA cases at autopsy 
in young subjects (<15 years of age) can be explained by channelopathies, 
such as Brugada syndrome, long (LQTS) and short (SQTS) QT syndrome and 
cathecholaminergic polymorphic ventricular tachycardia (CPVT) (35). A new 
structural substrate has been recently described for the first time in association 
to OHCA, occurring especially in young adult women: myocardial fibrosis of the 
papillary muscle and basal inferolateral wall have been described as the 
structural hallmark in mitral valve prolapse patients experiencing SCD (36).  
Post-mortem studies have also shown a correlation between OHCA and some 
non-specific anatomical and functional findings, in apparently normal hearts, 
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that are still under debate (18)(19): mild left ventricular hypertrophy in the 
absence of hypertension, atrial fibrillation, mild conduction system disease and 
the presence of interstitial myocardial fibrosis. 
 
1.2 Diagnosis  
 
1.2.1 Urgent coronary angiography 
Secondary to the high prevalence of atherosclerotic lesions among OHCA 
survivors and at post-mortem studies of patients experiencing SCD (15), the 
European guidelines recommend to perform urgent coronary angiogram in view 
of primary percutaneous coronary intervention (PCI) in patients with 
resuscitated cardiac arrest with evidence of ST segment elevation (STE) on the 
first electrocardiogram (ECG) post recovery of spontaneous circulation (ROSC) 
(class I, level of evidence B) (37). However, it has been shown that obstructive 
or thrombotic “acute coronary syndrome” lesions can be found in 25%-58% of 
cardiac arrest cases with no evidence of ST elevation myocardial infarction 
(STEMI) on the first post-ROSC ECG (38). To strengthen the relation between 
CAD and OHCA, the latest 2017 ESC guidelines on STEMI have once again 
confirmed the indication to perform urgent coronary angiogram also in OHCA 
patients without diagnostic ST segment elevation, but with a high clinical 
suspicion of on-going infarction (class IIa, level of evidence C) (37). 
Coronary angiography in OHCA survivors shows three different scenarios: 1) 
typical “ACS” culprit lesion, 2) obstructive CAD with stable appearance and 3) 
unobstructed coronary arteries (38). When a clear “ACS” culprit lesion is 
identified on urgent angiography, immediate PCI with flow restoration is the best 
strategy to improve the haemodynamic status, to reduce infarct size and cardiac 
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arrest recurrence, and to improve patient’s survival; less clear is the relation 
between OHCA and stable CAD, as this might be due to transient ischemia on 
stable obstructive CAD (coronary spasm, plaque thrombosis with spontaneous 
recanalization) or it may just represent bystander disease. Nevertheless, 
although primary PCI and early revascularisation, respectively, significantly 
reduce SCD in STEMI and non-STEMI (NSTEMI) patients, sudden death early 
after MI, mainly secondary to mechanical complications, significantly impacts on 
overall deaths in this population (22). Finally, increasing attention is paid to 
myocardial infarction with non-obstructive coronary arteries (MINOCA), which 
has been shown to be involved in 1-14% of all MIs (37)(39); although an athero-
thrombotic cause can still be involved, other causes have to be encountered, 
such as myocarditis, Tako-Tsubo cardiomyopathy (TTC), and cardio-toxicity. 
Correct diagnosis in this subgroup of patients is of pivotal importance, as it 
implies different management and treatment strategy; non-invasive imaging, as 
will be discussed in detail later, plays an increasing and fundamental role in this 
setting.  
 
1.2.2 Cardiac imaging  
Current resuscitation guidelines do not recommend routine use of imaging, as 
they primarily aim at the resuscitation, peri- and post-resuscitation care of 
patients (40). However, multi-modality cardiac imaging is an important step in 
the correct diagnosis of OHCA causes, especially in patients without evidence 
of a culprit coronary lesion, and is determinant in guiding subsequent 




1.2.2.1 Trans-thoracic echocardiogram 
Trans-thoracic echocardiogram (TTE) can be useful in the identification of 
reversible causes of OHCA, such as cardiac tamponade or pulmonary 
embolism (non-cardiac cause of cardiac arrest, usually presenting as pulseless 
electrical activity) (41) and it successfully establishes the lack of cardiac activity 
during cardiac arrest. Focused TTE is recommended by the American Society 
of Echocardiography and by the American College of Emergency Physicians in 
order to identify the presence/absence of cardiac activity, assess biventricular 
function, identify the presence of pericardial effusion/tamponade in order to 
guide pericardiocentesis, and to confirm transvenous pacing wire placement 
(42)(43); comprehensive TTE or other imaging modalities are strongly 
recommended in cases of discordance between clinical presentation and 
findings on focused TTE. The guidelines strengthen the intrinsic limitations of 
TTE during resuscitation (technical difficulties related to on-going CPR, air in 
the stomach from bag-ventilation, presence of defibrillation pads) and 
recommend that TTE performance should never delay resuscitation 
manoeuvres or defibrillation; actually, it has been shown that focused TTE in 
pulseless electrical activity (PEA) cardiac arrest improves outcome by 
decreasing time to treatment (as a consequence of identification of underlying 
cause) and to ROSC. In order to avoid any delay in resuscitation manoeuvres, 
point-of-care (POC) focused echocardiography, which is performed during 
pulse-check intervals, has been proposed with the aim of diagnosing reversible 
causes of cardiac arrest, such as hypovolemia, cardiac tamponade and 
pulmonary embolism (44)(45), without interfering with resuscitation 
manoeuvres. POC TTE has shown to be a poor predictor of survival, but the 
identification of ventricular wall motion has shown to increase the likelihood of 
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ROSC from 2.4% to 51.6% (44). A recent meta-analysis on more than 1500 
patients has shown that POC is mainly used to predict resuscitation outcome 
(only guiding decision to terminate resuscitation manoeuvres) and to identify 
reversible causes of cardiac arrest (45); however, it is limited by operator-
dependency and by the need of a learning curve to perform focused TTE in 
non-ideal, emergency conditions; performing focused TTE during cardiac arrest 
is recognised as a core skill by many professional organisations (44). A 
comprehensive TTE once haemodynamic stability has been achieved is 
however the first line imaging technique for the assessment of global cardiac 
function, for differential diagnosis of the underlying causes of OHCA and also 
for in hospital follow-up of clinical improvement.  
 
1.2.2.2 Cardiovascular Magnetic Resonance 
Despite not being the first line imaging technique, the role of cardiovascular 
magnetic resonance (CMR) in the diagnostic assessment of patients surviving 
OHCA has increased over the past few years (46). As it will be discussed in 
details in the following chapter, the diagnostic role of CMR primarily relies on its 
ability to provide unique tissue characterisation, after administration of 
gadolinium-chelate contrast media: the presence, extent and distribution pattern 
of late gadolinium enhancement (LGE) allow the precise definition and 
differential diagnosis between IHD and NIHD (47). CMR was able to identify the 
underlying cause of cardiac arrest in more than two thirds of cases among 50% 
of OHCA survivors that had no clear diagnosis after a comprehensive clinical, 
electrocardiographic and imaging assessment (coronary angiogram and TTE) 
(48). Further evidence was provided by a similar study on OHCA survivors 
referred to CMR because of the absence of a clear diagnosis after a 
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comprehensive clinical, ECG and imaging assessment, which showed that 
CMR could identify a structural substrate for the cardiac arrest in 76% of 
patients (49). Finally, as previously described, MINOCA represent a non-
negligible proportion of OHCA causes; in this setting CMR has an incomparable 
role, secondary to its ability to characterise both acute (i.e. oedema) and 
chronic myocardial damage, and the use of CMR within 2 weeks from the index 
event has been recently recommended for the diagnosis of the underlying 
cause (37)(50).  Of course, the performance of a CMR scan requires the patient 
to be haemodynamically stable and, preferably, in spontaneous breathing, and 
this is way CMR is often postponed or, worse, not routinely performed in OHCA 
survivors. Moreover, patients surviving out of hospital cardiac arrest are often 
implanted with an ICD; as it will be further discussed in the next chapter, this 
usually requires waiting 6 weeks after endo-cavitary placement of the electrical 
leads in order to safely scan the patients, even in the case of MR-conditional 
devices.  
 
1.2.2.3 Cardiac nuclear imaging 
Cardiac nuclear imaging may also play a complimentary role in the assessment 
of cardiac arrest survivors, especially when it comes to defining arrhythmic risk, 
both in ischemic and non-ischemic cardiomyopathies (33). Single photon 
emission computed tomography and positron emission tomography play a role 
in the identification and quantification of myocardial scar, which is displayed as 
areas of fixed perfusion defects. The main role of these imaging modalities in 
the setting of ischemic cardiomyopathies comes from the identification of 
myocardial innervation-perfusion mismatch: nerve terminals are more 
susceptible to ischemia than cardiomyocites, so that as a consequence of 
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myocardial infarction, viable myocardium may have impaired denervation; 
studies with nuclear medicine have shown that the greater the extent of 
myocardial denervation, the higher the number of ICD shocks at follow-up. 
Finally, positron emission tomography combines information on myocardial 
perfusion and inflammation, thus playing a pivotal role in the assessment of 
disease activity in sarcoidosis: a pattern of active inflammation on positron 
emission tomography was associated with a considerable increase in 
ventricular arrhtyhmias and death as compared to a normal study (33).  
 
1.3 Management and early treatment 
 
1.3.1 Post resuscitation care 
The post resuscitation care is at least as important as the resuscitation phase, 
and big effort has been put in the identification of the best clinical practice 
aiming at increasing patients’ survival after OHCA and prevent recurrences.  
The latest European Resuscitation Council (ERC) guidelines (51) first 
emphasized, as one of the major post-resuscitation care, the importance of an 
urgent coronary angiogram in view to primary PCI in all OHCA survivors with 
suspected ischemic cause, as per the latest ESC guidelines previously 
described. The post-cardiac arrest syndrome mainly encounters brain injury and 
myocardial dysfunction, which mostly affect patients’ survival after aborted 
SCD: myocardial dysfunction, which is common after OHCA and usually starts 
recovering within 2-3 days, is mostly responsible of early deaths (within the first 
3 days), while brain injury is the leading cause of later deaths.   
Fever has been proven to be one of the strongest predictors of poor outcome 
(51) and that is why therapeutic hypothermia has been for long time recognised 
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as the best practice to reduce neurological injury after OHCA, by reducing both 
brain metabolism and exposure to toxins. However, the Targeted Temperature 
Management (TTM) Trial has recently shown no difference in outcome (death 
and neurological outcome) in OHCA survivors of a cardiac cause treated at a 
temperature of 33°C vs 36°C (52).  
 
1.3.2 Prevention of recurrences 
Prognosis of OHCA survivors varies significantly according to first rhythm, with 
survival rates ranging from 7.4% after PEA arrest, to 27.1% after VF arrest (53). 
Many trials have tested the benefit of secondary prevention ICD implantation in 
patients surviving OHCA, showing markedly reduced adverse events rate 
among patients treated with ICD as compared to maximal anti-arrhythmic 
treatment. European guidelines recommend ICD implantation in patients with 
documented VF or haemodinamically non-tolerated VT in the absence of 
reversible causes (IA); ICD implantation should also be considered (IIaC) in 
patients with recurrent sustained VT (not within 48 hours from MI) who are 
receiving optimal medical therapy (54). Patients surviving OHCA are exposed at 
a higher risk of recurrent arrhythmic events: a small study on 18 patients with 
IVF (Brugada syndrome and the other channelopathies were systematically 
excluded from the study) showed a recurrence rate of VF, appropriately treated 
by ICD, of 39% with a mean time to first event of 12±9 months (55). Data on 
recurrence of adverse events after the first cardiac arrest vary significantly 
among different registries, with 51% ICD discharge within the first year in the 
Antiarrhythmic versus implantable defibrillators (AVID) trial, which enrolled 
patients surviving VF arrest or presenting with sustained VT and reduced LVEF, 
to 30% adverse events in primary prevention in the Sudden Cardiac Death in 
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Heart Failure (SCD-HeFT) trial within the first three years of follow-up. The vast 
heterogeneity in ICD discharge rate in OHCA survivors is at least in part 
explained by the different ICD programming: longer detection intervals have 
now been proven to be effective in reducing ICD therapies without increasing 
risk of adverse events, and are expected to change recurrence rates if 






















Chapter 2. Cardiovascular Magnetic Resonance 
 
Cardiovascular magnetic resonance (CMR) is a multi-parametric, multi-planar, 
non-invasive imaging modality, which does not require the use of ionising 
radiation. Due to its higher spatial resolution, higher blood pool-epicardium 
contrast and superior tissue characterisation, it is an increasingly used imaging 
technique, also in daily clinical practice. CMR scanners commonly used in 
clinical practice have 1.5T or 3T field strength, which equals respectively 30000 
and 60000 times the magnetic field of the Earth. A CMR scanner consists of the 
main static magnetic coil (B0), the gradient coils and the radiofrequency 
transmitter coil.  
 
2.1 Basic CMR physics 
The physics of CMR exploits a basic concept, that 90% of human body is made 
of water. Looking at the nuclei, hydrogen protons are positively charged and 
they continuously move around an axis, they spin. As for physics principle, 
electrical charges in motion generate a magnetic field; when protons are put 
into a magnetic field (i.e. the magnetic field of a CMR scanner, B0), they can 
either align along the direction of the magnetic field, or align in the opposite 
direction, but given that less energy is required to align along the direction of the 
external magnetic field, an excess of protons will align along the direction of the 
external magnetic field B0, generating a net magnetic moment (Mz, longitudinal 
magnetisation). The protons put into an external magnetic field B0 will continue 
to move (precess), with a frequency, which is proportional to the intensity of the 
external magnetic field B0; this is described by the Larmor equation: ω0=Υ B0 
(ω0 is the precession frequency, expressed in Hz or MHz, Υ is the gyro-
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magnetic ratio, that is 42.5 MHx/T for protons, and B0 is the external magnetic 
field).  If a patient is put inside a 1.5T CMR scanner, the protons will align along 
the direction of the external magnetic field B0 and will start precessing, but it is 
not possible to measure the magnetic field generated and a radiofrequency 
(RF) pulse has to be sent to alter the equilibrium. As it is easier to exchange 
energy between molecules that share similar properties, in order for the RF 
pulse to be able to exchange energy with the protons, the RF needs to have a 
specific frequency, similar to those of the protons.  As the RF pulse is sent, the 
protons pick up energy (this process is called “resonance”) and by doing so 
some of the protons will go from a lower to a higher level of energy, and some 
will align in the direction opposite to that of the external magnetic field B0, so 
that overall the longitudinal magnetisation Mz will decrease; however, the RF 
pulse will make the protons precess synchronously, in phase, generating 
another magnetic field, pointing to the side to which the protons precess, which 
is called transversal magnetisation (Mxy) (Figure 1).  
 
 
Figure 1. Longitudinal and transversal magnetisation. A) After the 
radiofrequency (RF) pulse is sent, protons pick up energy and change their 
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alignment along the external magnetic field; as a result, longitudinal 
magnetisation (Mz) decreases. B) The RF pulse, however, makes the protons 
precess in phase so that a new, transversal, magnetisation (Mxy) is generated. 
 
When the RF pulse stops, the protons go back to their initial state and hand 
over their energy to the surroundings: the longitudinal magnetisation builds up 
again and the time needed to recover 63% of the original longitudinal 
magnetisation M0 is described by the T1 relaxation or longitudinal (spin to 
lattice) relaxation; this depends on the field strength and on the tissue in which 
the relaxing protons are. The RF pulse had the role to make the protons 
precess in phase, so when the RF pulse stops, the protons do not precess in 
phase anymore, there is a loss of coherence and the transversal magnetisation 
decreases: the T2 relaxation or transversal (spin to spin) relaxation describes 
the time needed for the signal to decay to 37% of its original value. The 
magnetic field is per se inhomogeneous, and when this inhomogeneity is 
combined with T2 relaxation, this is called T2* relaxation (56).  Different tissues 
have different T1 and T2 relaxation times (Figure 2), and this is at the basis of 
the tissue characterisation provided by CMR. Generally, T1 is longer than T2 
(300-2000 msec vs 30-150 msec). T1 depends on tissue composition and on 
the surroundings. Water molecules, for example, are small and move quite 
rapidly, so energy handover is difficult and takes longer: fluids have long T1 
relaxation; moreover, by moving fast, their local magnetic fields fluctuate fast 
and there is not a big difference in magnetic field: fluids have long T2. The 
carbon bonds at the end of lipids molecules have precession frequency very 
close to Larmor frequency, so that the exchange of energy is quick: T1 of fat is 
short. T1 relaxation can be altered by contrast administration: gadolinium-
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chelate contrast agents shorten T1 relaxation time, and this is at the basis of T1 
weighted post-contrast imaging.  
 
Figure 2. Coupling of the T1 and T2 relaxation curves. T1 relaxation is normally 
longer than T2 relaxation.  
 
Contrast-weighting imaging is the key component of the clinical application of 
CMR, as it is responsible of the superior tissue characterisation provided by this 
technique. Contrast-weighting imaging is based on different timing parameters: 
repetition time (TR), which is the time between two RF pulses, and echo time 
(TE), which is the time between the RF pulse and the signal acquisition. The 
greatest difference in T1 relaxation of different tissues is at the beginning of the 
recovery of longitudinal magnetisation, so right after the RF pulse has been sent 
in: T1 weighting is greater with short TR (i.e. 500 msec); this is however at the 
expense of signal, which is low, as magnetisation has not recovered enough 
yet. Nevertheless, when image is acquired with long T1 (i.e. 1500 msec) 
longitudinal magnetisation has fully recovered, so signal is high, but at the 
expense of very small differences in T1 relaxation of different tissues, and thus 
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T1 weighting is very modest. Once RF pulse is stopped (i.e. with short TE, 30 
msec), the transversal magnetisation is at the maximum value, so signal is high, 
but there is no difference in T2 relaxation of different tissues, so that T2 
weighting is very modest. Transversal magnetisation then starts decreasing, 
and the more time passes by, the more the decay in T2 relaxation and the 
greatest the difference in T2 weighting between different tissues: T2 weighting 
is characterised by long TE (i.e. 80 msec). Short TR and short TE are used to 
obtain T1 weighting, while long TR and long TE are used for T2 weighting.  
The energy handed over by the protons to the surroundings, once the RF pulse 
stops, is measured and post-processed to create an image. All MR signals 
acquired need to have a precise location in space, and this is achieved on CMR 
in different steps. First of all, a selected range of RF is usually sent in, to 
exchange energy only with protons with a specific Larmor frequency, so that the 
wider the range of RF pulses, the thicker the slice of the body imaged. A 
frequency-encoding gradient is then applied on the y-axis: the different 
magnetic field values correspond to different precession frequencies. Finally, a 
phase encoding gradient is applied on the x-axis, to enhance protons with the 
same precession frequency, but with different phases.  By applying multiple 
phase encoding and frequency-encoding gradients it is possible to precisely 
localise every single MR signal; time-dependent MR signals are then expressed 
as different frequency components through a mathematical process (the Fourier 
transform), so that it is possible to know exactly how much MR signal of a 
specific frequency and phase is coming out of each point in space. All digitized 
MR signal data are then stored into the k-space, which is a data matrix; the 
matrix of the k-space equals in size the matrix of the field of view of the image. 
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2.2 Cardiac function 
Cardiovascular magnetic resonance is the gold standard for the assessment of 
biventricular volumes and function (57)(58) and its main advantage over 2D 
echocardiography is based on its independence on any geometrical 
assumption. Volumes and systolic function assessment on CMR are based on 
3D whole heart coverage, which is guaranteed by short axis cine imaging, from 
the mitral valve plane to the cardiac apex. The endocardium and epicardium of 
each short axis slice are contoured in end-diastole (image with the largest blood 
volume) and end-systole (image with the smallest blood volume) on each slice, 
in order to provide global ventricular volumes and ejection fraction, both for the 
left and right ventricle. As per the standardized image interpretation and post-
processing in CMR of the Society for Cardiovascular magnetic Resonance 
(SCMR) Board of Trustee Task Force recommendations (59) the LV outflow 
tract is included as part of the LV blood volume and attention should be paid 
when drawing contours of the most basal slices, in order to omit slices 
containing atrial blood volume; papillary muscles are myocardial tissue and 
should ideally be included with the myocardium, but their exclusion is 
acceptable.  
 
2.3 Tissue characterisation 
The key property of CMR is its ability to provide a detailed tissue 
characterisation, to a level superior to any other imaging modality: this is based 
on the different weighting of the images, which allows the detection and 
differentiation of tissue components, such as fibrosis and oedema.  
CMR uses gadolinium-chelate contrast agents, which are administered intra-
venous, but have an extra-vascular distribution: gadolinium-chelate contrast 
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agents are quickly washed out by normal myocardium, but accumulate in the 
extra-cellular space, even more so in those conditions where extra-cellular 
space is pathologically increased; this can be due to myocardial membrane 
rupture secondary to acute damage, or to collagen deposition in the context of 
chronic myocardial scar. Myocardial fibrosis can be seen on CMR as infarct, 
replacement fibrosis or diffuse fibrosis, which have been shown to represent a 
continuum of myocardial damage in patients with IHD: 70% of myocardial 
fibrosis in IHD is represented by diffuse and replacement fibrosis, while only 
30% is represented by infarct (60). Gadolinium-chelate contrast agents shorten 
T1 relaxation and areas of contrast accumulation appear bright (white) on T1 
weighting imaging, performed 10-15 minutes after contrast injection (late 
gadolinium enhancement, LGE). The widest application of CMR has been in the 
assessment of ischemic cardiomyopathy (61)(62) and its ability to detect 
myocardial fibrosis has been validated against histology: myocardial fibrosis 
seen on CMR faithfully reproduced the infarcted areas seen on pathologic 
specimen on animal models (63). CMR has also been shown to be superior to 
SPECT in the assessment of infarcted areas, especially those of small size and 
with non-anterior location (64).  
Based on the distribution pattern of LGE, it is possible to clearly distinguish 
cardiomyopathy of ischemic or non-ischemic origin (47). Following the ischemic 
wave-front phenomenon, which proceeds from the subendocardium to the 
entire wall thickness, an ischemic distribution of LGE involves the 
subendocardium, from which it can extend within the wall thickness, to become 
transmural; ischemic LGE is also located along the territory of distribution of a 
coronary vessel. On the other hand, non-ischemic processes neither follow the 
ischemic wave-front phenomenon, nor the territory of distribution of a coronary 
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vessel, and usually present as epicardial, mid-wall or a combination of both. 
The most recent CMR software not only allows the identification of LGE 
(presence/absence) but also provide its quantification, in absolute terms (grams 
of fibrosis) and as percentage of the LV mass. Quantification is based on signal 
intensity, which means that myocardial fibrosis is identified as a signal intensity 
deviating from that of the remote (normal) myocardium. Different studies have 
tested different thresholds of signal intensity (2 standard deviations, SD, 3SD, 
5SD, 6SD) in order to correctly identify myocardial scar; most of them identified 
the cut-off for abnormal signal intensity at 5SD above that of remote 
myocardium, but recently the full width at half maximum (FWHM) technique, 
which uses half the maximal signal intensity within the scar as threshold, has 
been shown to be the most accurate and reproducible, irrespective of the 
underlying structural disease (65).   
As previously mentioned, fluids have long T1 and T2 and appear bright (white) 
on T2 weighted images, thus allowing depiction of myocardial oedema. CMR 
can detect myocardial oedema as early as 30 minutes after chest pain onset  
and although there is no agreement on the actual mean persistence of 
myocardial oedema after an acute event, it can usually be seen for a couple of 
weeks up to a couple of months, persisting also once cardiac biomarkers have 
normalised (66).  
Assessment of myocardial oedema has important implications both in ischemic 
and non-ischemic cardiomyopathies. Approximately one third of ACS patients 
do not have a culprit lesion on angiogram (67); myocardial oedema sequences 
help identify the “infarct-related” artery, as an area of increased signal intensity 
along the territory of distribution of the culprit coronary artery. Quantification of 
myocardial oedema after an acute MI allows the identification of the area at risk 
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(the area that would become necrotic if the infarcted artery was not to be 
treated) and the myocardial salvage (expressed as the difference between the 
area at risk and the LGE area) which represents the amount of myocardium 
“rescued” after treatment of the infarct related artery: the presence of an area at 
risk identifies patients that will benefit from an early invasive treatment (68), also 
considering that myocardial oedema has been linked to adverse cardiovascular 
events, irrespective of revascularisation (69)(70). Both the assessment of the 
area at risk and of the myocardial salvage have been validated, versus the gold 
standard fluorescence microsphere (71) and versus SPECT, respectively (66).   
Analysis of oedema sequences has gained an increasing role in the setting of 
MINOCA (50)(72). Plaque rupture, coronary vasospasm and embolization, that 
can appear on angiogram as non-flow limiting stenosis or as unobstructed 
arteries, can still be responsible of acute myocardial damage. This can be easily 
identified on CMR, especially if performed within two weeks from the index 
event (50)(67)(73): on T2 weighted images, myocardial oedema has an 
ischemic, often transmural, pattern, along the territory of distribution of a 
coronary artery (74). A meta-analysis on 500 patients presenting with MINOCA 
showed that up to a third have findings consistent with myocarditis (75), and 
CMR has been recently recommended by European guidelines as first line 
imaging technique, in stable patients with suspected myocarditis,  prior to 
endomyocardial biopsy (76): Lake Louise criteria on CMR (myocardial oedema 
on the T2 weighted images, hyperemia on the early gadolinium enhancement 





2.4 Myocardial deformation analysis 
Myocardial architecture is very complex and is organised in three layers: the 
subendocardial layer, where fibres are oriented obliquely from base to apex 
(right-handed helix), the mid-wall layer, where fibres are circumferentially 
oriented, and the epicardial layer, where fibres are still oriented obliquely, but 
from apex to base (left-handed helix).  As a consequence of this complex 
structure, during systole, the LV deforms along different directions, shortening in 
the circumferential and longitudinal direction, and thickening in the radial 
direction. Myocardial deformation imaging assesses the complex changes of LV 
myocardium during contraction, by measuring the degree of deformation of 
myocardial segments from the initial length (in end-diastole) to the maximum 
length (usually in end-systole), which is known as myocardial strain, and 
expressed as percentage (78)(79)(80). Myocardial strain can be measured 
along the three directions of LV deformation, longitudinal, radial and 
circumferential. The global longitudinal strain (GLS) represents myocardial 
shortening along the longitudinal direction, from base to apex, and has negative 
values; global radial strain (GRS) represents myocardial thickening along the 
radial direction, and has positive values; global circumferential strain (GCS) 
represents myocardial shortening along the circular perimeter (observed on a 
short- axis view), and has negative values. Different CMR sequences have 
been developed over the years in order to quantify myocardial deformation, 
from the earliest tagging sequences to the latest feature and tissue tracking 
(81)(82)(83)(84). Feature and tissue tracking technology is the latest strain 
analysis technique and is a post-processing method that tracks myocardial 
features on different cardiac phases on the cine sequences; post-processing 
software identify a myocardial feature in one cardiac frame and then the “as 
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much as possible similar” feature in the next frame (84)(85).  Feature and tissue 
tracking software rely on the tracing of endocardial and epicardial borders, in 
two long axes and in the short axis cine stack, at end-diastole: features traced 
are then automatically tracked throughout the cardiac cycle (Figure 3). Different 
studies have shown a good agreement between CMR-derived strain and 
speckle tracking echocardiography (SpTE) (86)(87); however, SpTE-derived 
longitudinal strain has shown to be more accurate than feature tracking CMR, 
which in turn shows more reproducible measurement of circumferential strain 
(84). Some technical issues affect myocardial strain assessment repeatability: 
the global estimation of strain is more reliable and more reproducible than the 
segmental analysis (84), which suffers of through-plane motion, both on SpTE 
and CMR (88). Analysis of myocardial deformation is increasingly used in 
clinical practice, also because it has been shown to impair prior to the reduction 
of ejection fraction, thus representing an early disease marker; the earlier 
impairment of longitudinal strain as compared to LVEF has been attributed to 
higher sensibility of subendocardium to different sort of injuries (89). The ability 
of longitudinal strain to detect early LV dysfunction has shown to be very useful 
for example in HCM, where LVEF is usually normal or supra-normal but LV 
function is impaired: in these patients, despite a normal LVEF, longitudinal 
strain appears abnormal (89). In a meta-analysis on more than 5000 patients 
with different cardiac conditions, global longitudinal strain was the stronger 
predictor of all-cause mortality when compared with LVEF, with a strength of 
effect for the HR per standard deviation for global longitudinal strain 1.19 times 
greater than that of LVEF (90). As myocardial strain reflects the complex 
layered myocardial structure, it has shown to be particularly useful in layer-
specific cardiomyopathies: circumferential strain has been shown to be 
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significantly different in normal myocardium as compared to areas with 
subendocardial or transmural MI (91)(92). The capability of some strain analysis 
software to assess layer-specific strain values (endocardial vs epicardial) allows 
the differentiation of myocardial segments with subendocardial or transmural 
MI, as both endocardial and epicardial strain decrease with the increase in LGE 
transmurality (91). Regional variations in myocardial strain, although less 
reproducible, correlate with regional LGE in post-MI patients (93), and 
myocardial strain impairment has shown close correlation to the presence of 
myocardial LGE, in a way that is proportional to its size and transmural extent 
(94)(95). Similarly, a strong association has been found between impairment of 
circumferential shortening in DCM patients with mid-wall fibrosis (96), as mid-
wall fibres are those responsible of circumferential shortening. Myocardial strain 
appears to be a very sensible detector of subtle myocardial dysfunction, as 
shown in HCM patients, where impaired strain goes beyond hypertrophied 
segments (97). 
 
Figure 3. Myocardial strain analysis by tissue tracking. Endocardial (red) and 
epicardial (green) contours are traced in two long axes cine (A, B) and in the 
short axis cine stack images (a mid-cavity slice is shown in C). The software 
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tracks the features traced throughout the cardiac cycle and displays myocardial 
deformation (longitudinal strain is shown in D).   
 
2.5 Contraindications to CMR 
Contraindications to CMR are related to the three main components of the CMR 
imaging, the static magnetic field, the gradient fields and the RF pulses. 
Secondary to the static magnetic field, any ferromagnetic material accelerates 
towards the magnetic core, with the risk of projectile injury any time a 
ferromagnetic material is introduced in the room where the CMR scanner is 
located. The gradient magnetic field is responsible of the noise (>90 dB), with 
consequent potential auditory damage (patients do however always wear 
headphones), and mainly of promoting current induction and device malfunction 
of medical devices. RF pulses are mainly responsible of heating effects of any 
medical implant.   
Absolute contraindications to CMR include: ferromagnetic cerebral aneurysm 
clips/ocular implants, foreign ocular metallic bodies, cochlear implants, 
neurostimolators; CMR should also not be performed in the first trimester of 
pregnancy, in patients with severe renal impairment (GFR < 30 ml/min/1.73 m2) 
and in patients with severe claustrophobia. An important consideration with 
regards to MR-safety has to be made about cardiac implantable devices, such 
as ICD and pace-makers, as MR-conditional, and more recently MR-safe, 
cardiac implantable devices can be safely scanned following manufacturers 
instructions (conventional cardiac devices can also be scanned with low risk if 
appropriate precautions are taken, i.e. programming asynchronous pacing in 
pace-maker-dependent patients); if leads are not matured (<6 weeks after 
implantation), broken or abandoned a cardiac MR should not be performed 
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given the risk of dislodgement. Nephrogenic systemic fibrosis (NSF) is a rare 
condition presenting with dermal lesions and involvement of internal organs, 
which can be lethal; it is most likely related to the contrast agent used, but it 
appears to manifest only in patients with severe renal failure (GFR < 30 
ml/min/1.73 m2). However, it has been shown that the risk of NSF approximates 
zero in patients receiving a contrast dose according to the labelling (i.e. 
Gadobutrol 0.1 mmol/kg), irrespective of renal function (98). 
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Chapter 3. Background 
Impact of cardiovascular magnetic resonance on clinical 
management and decision-making in out of hospital cardiac 
arrest survivors with inconclusive coronary angiogram (99)  
Reprinted from (99) Resuscitation 116 (2017), A. Baritussio, A. Zorzi, A. Ghosh Dastidar, A. 
Susana, G. Mattesi, J.C.L. Rodrigues, G. Biglino, A. Scatteia, E. De Garate, J. Strange, L. 
Cacciavillani, S. Iliceto, A. Nisbet, G.D. Angelini, D. Corrado, M. Perazzolo Marra, C. Bucciarelli-
Ducci,  Out of hospital cardiac arrest survivors with inconclusive coronary angiogram: Impact of 
cardiovascular magnetic resonance on clinical management and decision-making, Pages No. 
91–97, Copyright (2017), with permission from Elsevier.  
 
3.1. Background 
Urgent angiography with view to primary percutaneous coronary intervention is 
a class IB recommendation in patients with resuscitated cardiac arrest whose 
electrocardiogram (ECG) shows STEMI. Given the high incidence of underlying 
CAD in this group of patients, European guidelines extended the 
recommendation to incorporate patients without diagnostic STE, but with high 
suspicion of on-going infarction (class IIaC). However non-ischemic 
cardiomyopathy accounts for up to 15% of OHCA and a structurally normal 
heart can be found in up to 10–20% of cases (99). While evidence of culprit 
lesion on angiogram supports acute ischemia as the cause of OHCA, diagnosis 
and clinical management of OHCA survivors with inconclusive coronary 
angiogram (either non-identifiable culprit lesion or unobstructed coronary 
arteries) is challenging. Cardiovascular magnetic resonance is a non-invasive 
imaging technique providing accurate diagnosis based on its superior spatial 
resolution and unique non-invasive tissue characterization.  
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3.2 Materials and methods 
The CMR registries from two tertiary centres (Bristol, South West of England 
and Padua, Veneto Region, Italy) were analysed to identify OHCA survivors 
who underwent urgent coronary angiogram followed by CMR (October 2009-
November 2015). The study focused on the analysis of patients with an 
“inconclusive angiogram”, defined as evidence of stable obstructive CAD 
(SCAD) with no culprit lesion or unobstructed coronaries (normal 
coronaries/non-obstructive CAD). Culprit lesion was defined as obstructive 
(≥70%) CAD with TIMI 0/1 flow with abrupt closure, or TIMI 2/3 flow with 
features suggestive of thrombus/ulcerated plaques, ST segment-T wave 
changes in the corresponding ECG location, and evidence of matching regional 
wall motion abnormality on left ventriculogram or echocardiogram (37)(101).  
CMR was performed on a 1.5T scanner (Avanto, Siemens Health- care, 
Germany) with a protocol including long and short axis cine sequences and 
post-contrast imaging, performed ten minutes after intravenous administration 
of 0.1 mmol/Kg of Gadobutrol (Gadovist 1.0 mmol/ml, Bayer-Schering, Berlin, 
Germany) in identical planes to cine images. Additional sequences for the 
assessment of myocardial oedema (T2-short tau inversion recovery, T2-STIR) 
or myocardial ischemia (stress perfusion with 140–210 ug/Kg/min adenosine) 
were performed when indicated, based on clinical and angiographic findings. 
Ventricular function was assessed with dedicated software (Circle 
Cardiovascular Imaging, Calgary, Canada), by tracing endo- and epicardial 
borders on each short axis cine slice in end-diastole and end-systole. All 
volumes were indexed to body surface area. The localization, extent and 
distribution pattern of late gadolinium enhancement (LGE) were assessed by 
using short- and long-axis views and confirmed only if detectable in two 
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orthogonal planes. The pattern of LGE distribution was defined as ischemic, 
subendocardial or transmural, if involving <50% or ≥50% of wall thickness, 
respectively, and as mid-wall/epicardial if patchy/spotty intra-mural or sub-
epicardial enhancement was detected. The presence of LGE at the right 
ventricle/left ventricle insertion points, in the absence of other distribution 
patterns, was defined as non-specific findings, as its diagnostic and prognostic 
meaning is still unclear. All the analyses were carried out in accordance with the 
recommendation of the Society for Cardiovascular Magnetic Resonance (59).  
The study was reviewed by the local Institutional Research and Innovation 
Department and in view of the retrospective design, formal ethical approval was 
waived off. All patients gave written informed consent.  
Clinical, ECG and echocardiographic data were collected and independently 
analysed by two clinicians blinded to CMR findings. A diagnosis was made 
based on clinical and imaging data available prior to CMR. According to 
previously used definitions (102), “clinical impact” of CMR was defined as 
change in diagnosis, compared to the composite pre-CMR diagnosis, or change 
in management. A change in management was defined as CMR findings either 
leading to change in medication, to an invasive procedure (i.e. repeat 
angiogram, myocardial revascularization, ICD implantation) or to the avoidance 
of such invasive procedures. Patients with a change both in diagnosis and 
management were only counted once.  
 
3.3 Statistical Analysis 
Continuous and categorical variables were expressed as mean±SD or median 
(IQR), and n (%), respectively. Categorical variables were compared by using 
the chi-square or Fisher exact test, as appropriate. Continuous data were 
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compared by using the 2-tailed unpaired t test (for normally distributed data 
sets) or by using the Mann-Whitney U test. Inter-rater agreement for categorical 
variables was assessed by Cohen’s kappa coefficient. A p-value of <0.05 was 





Out of 174 consecutive OHCA survivors referred to CMR after coronary 
angiogram (performed on same day of admission, IQR 0-2 days), 110 patients 
(63%, 84 male, age 58 years, IQR 46–68) had an inconclusive angiogram and 
were enrolled in the study: 37 patients (34%) had evidence of SCAD with no 
culprit lesion and 73 patients (66%) showed unobstructed coronaries. The first 
registered rhythm was ventricular tachycardia (VT)/ventricular fibrillation (VF) in 
104 patients (95%) and pulseless electrical activity (PEA) in 6 patients (5%). 
The first ECG was available in 86 patients (78%): non-ST elevation (non-STE) 
was reported in 68 patients (79%), STE in 18 (21%). SCAD patients with no 
culprit lesion were more frequently men (p=0.006) and significantly older 
compared to patients with unobstructed coronaries (p<0.001); risk factors were 
similar, except for hypertension (p=0.001) and known CAD (p<0.001), which 
were more frequent among SCAD patients with no culprit lesion. STE was more 
common among SCAD patients with no culprit (p=0.002). Patients’ 





Table 1. Clinical characteristics 
 
Values are expressed as n (%) and median (IQR). SCAD, stable CAD with no 
culprit lesion; CAD, coronary artery disease; SCD, sudden cardiac death; NIHD, 
non-ischemic heart disease; VT, ventricular tachycardia; VF, ventricular 
fibrillation; PEA, pulseless electrical activity; ROSC, recovery of spontaneous 
circulation; STE, ST segment elevation.  
 
CMR findings 
Among patients with inconclusive angiogram, CMR was performed within 2 
weeks from the index event (median 1.4 weeks, IQR 0.9-2.4, no difference 
between centres, p=0.588). Time to CMR was significantly shorter among 












Male 84 (76) 34 (92) 50 (68) 0.006 
Age, years 58 (46-68) 65 (58-75) 52 (40-63) <0.001 
Hypertension 36/100 (36) 20/35 (57) 16/65 (25) 0.001 
Diabetes 13/100 (13) 7/35 (20) 6/65 (9) 0.127 
Active smoking 25/100 (25) 11/35 (31) 14/65 (22) 0.276 
Hyperlipidaemia 20/100 (20) 10/35 (29) 10/65 (15) 0.116 
Family history CAD 9/100 (9) 4/35 (11) 5/65 (8) 0.533 
Family history SCD 2/100 (2) 0/35 (0) 2/65 (3) 0.295 
Previous CAD 24/100 (24) 17/35 (49) 7/65 (11) <0.001 
Previous NIHD 5/100 (5) 1/35 (3) 4/65 (6) 0.471 
VT/VF 104/110 (95) 34/37 (92) 70/73 (96) 0.383 
PEA 6/110 (5) 3/37 (8) 3/73 (4) 0.382 
ECG post ROSC, STE 18/86 (21) 11/27 (41) 7/59 (12) 0.002 
ECG post ROSC, non-STE 68/86 (79) 16/27 (59) 52/59 (88) 0.002 
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acute coronary event on angiogram (p=0.001). Median left ventricular ejection 
fraction (LVEF) was 57% (IQR 44–64), median indexed left ventricular end-
diastolic volume (LViEDV) and end-systolic volume (LViESV) was 87 ml/m2 
(IQR 73–110) and 38 ml/m2 (IQR 27–56), respectively. LVEF was significantly 
higher among patients with unobstructed coronaries (p<0.001). Wall motion 
abnormality was reported in 55 patients (50%), with regional or diffuse pattern in 
38 (35%) and 17 patients (15%), respectively (Table 2).  
On post-contrast sequences LGE was found in 72/110 patients (65%), and it 
was significantly more common among SCAD patients with no culprit lesion 
(33/37 vs. 39/73, p<0.001). Analysis of LGE distribution pattern showed 
subendocardial LGE in 15 patients (14%), mid-wall/epicardial in 26 patients 
(24%), and transmural LGE in 27 patients (25%). More than one distribution 
pattern was reported in 4 patients (3%). No LGE was found in 38 patients 
(34%). T2-STIR sequences for myocardial oedema were performed in 58 
patients (53%), more frequently in patients with unobstructed coronaries 
(p=0.001); myocardial oedema was found in 18 patients (31%). Presence of 
myocardial oedema was not significantly associated with the timing of CMR; 
however, there was a trend towards a higher prevalence of myocardial oedema 
among patients undergoing CMR within one week from index event (p=0.064). 




















LVEF, % 57 (44-64) 44 (34-55) 60 (52-65) <0.001 
LViEDV, ml/m2 87 (73-110) 94 (76-120) 86 (72-103) 0.132 
LViESV, ml/m2 38 (27-56) 48 (38-82) 35 (24-48) <0.001 
Regional WMA 38 (35) 23 (62) 15 (21) <0.001 
Diffuse WMA 17 (15) 7 (19) 10 (14) 0.474 
Myocardial oedema 18/58 (31) 5/11 (45) 13/47 (28) 0.251 
LGE 72 (65) 33 (89) 39 (53) <0.001 
Values are expressed as n (%) and median (IQR). LVEF, left ventricular 
ejection fraction; LViEDV, indexed left ventricular end-diastolic volume; LViESV, 
indexed left ventricular end-sistolic volume; WMA, wall motion abnormality; 
LGE, late gadolinium enhancement.  
 
Overall, CMR identified a pathologic substrate in 69% of the population: IHD 
was the final diagnosis in 45 patients (41%) and non-ischemic heart disease 
(NIHD) in 31 (28%). Non-specific findings were found in 9 patients (8%) and a 
structurally normal heart in 25 (23%)(Table 3). CMR findings between the two 








Table 3. CMR findings. 
CMR Diagnosis n = 110 
IHD 45 (41) 
NIHD 31 (28) 
                      - myocarditis 7 (6) 
                      - DCM 6 (5) 
                      - HCM 3 (3) 
                      - ARVC 3 (3) 
                      - TTC 3 (3) 
                      - cardiac amyloidosis 1 (1) 
                      - hypertensive heart disease 2 (2) 
                      - LVNC 1 (1) 
                      - HFpEF 1 (1) 
                     - MVP 4 (3) 
Structurally normal heart 25 (23) 
Non-specific findings 9 (8) 
Variables are n (%). IHD, ischemic heart disease; NIHD, non-ischemic heart 
disease; DCM, dilated cardiomyopathy; HCM, hypertrophic cardiomyopathy; 
ARVC, arrhythmogenic right ventricular cardiomyopathy; TTC, Tako-Tsubo 
cardiomyopathy; LVNC, left ventricular non compaction; HFpEF, heart failure 
with preserved ejection fraction; MVP, mitral valve prolapse. 
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Figure 4. CMR findings in OHCA survivors with inconclusive angiogram. Final 
CMR findings, according to coronary angiogram data, in OHCA survivors with 
inconclusive angiogram. Boxes in bold show the final CMR findings in the 
overall cohort of OHCA survivors with inconclusive angiogram. SCAD, stable 
coronary artery disease.  
 
Stable obstructive CAD with no culprit lesion 
Thirty-four patients (92%) were found to have IHD, a structurally normal heart 
(no myocardial oedema, late enhancement or inducible ischemia) was found in 
3 (8%). On T2-STIR sequences, performed in 11 patients (30%), myocardial 
oedema was found in a single coronary artery territory in 5 (45%), helping to 
localise the culprit lesion. Stress perfusion CMR was performed in 15 patients 
(41%): inducible ischemia was reported in 10 patients (67%) (single coronary 
artery territory in 7 patients and multi-vessel territory in 3), 90% of whom 
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received percutaneous/surgical revascularization. A viability study was 
performed in the remaining 22 (59%) to guide treatment 
(revascularization/optimization of medical therapy); CMR showed findings 
consistent with viable myocardium in 15 patients (68%), of which 12 (80%) 
underwent revascularization.  
 
Unobstructed coronaries 
IHD was diagnosed in 11 patients (15%) and NIHD in 31 (43%), with 
myocarditis (23%) and dilated cardiomyopathy (DCM) (10%) being the most 
common, followed by congenital and acquired cardiomyopathies (Table 3). A 
structurally normal heart was found in 22 patients (30%) and non-specific 
findings in 9 (12%)(Figure 5). On T2-STIR sequences, performed in 64% of 
patients, the presence of myocardial oedema in 13 (28%) identified an acute, 
reversible, cause of OHCA in 3 IHD patients and in those diagnosed with 




Figure 5. CMR findings. Post-contrast 3 chamber long-axis view showing 
transmural myocardial infarction (A). Post-contrast 3 chamber long-axis view of 
a patient with hypertrophic cardiomyopathy (HCM) and replacement fibrosis of 
the hypertrophied septum (B, arrow). Post-contrast 4 chamber long axis view of 
a patient with biventricular arrhythmogenic right ventricular cardiomyopathy 
(ARVC) (C). 3 chamber long axis cine showing prolapse of the posterior mitral 
leaflet at end-systole (D). Post-contrast short axis view showing epicardial 
enhancement of the basal lateral wall in a patient with healed myocarditis (E, 
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arrow). Post-contrast short axis view showing non- specific late enhancement of 
the inferior insertion point (F, arrow).  
 
Comparison between CMR and trans-thoracic echocardiogram 
A trans-thoracic echocardiogram (TTE) performed within 1 week from CMR was 
available in 92 patients (84%). Median LVEF by TTE was lower compared to 
CMR (50% vs 57%, p<0.001). TTE identified a pathologic substrate in 50/92 
patients (54% vs 69% by CMR, p = 0.018): the final diagnosis was IHD in 26/92 
patients (28%) and NIHD in 24/92 patients (26%). A structurally normal heart 
was found in 20/92 patients (22%) and non-specific findings (structural and 
functional abnormalities not attributable to a conclusive diagnosis) in 22 (24%). 
CMR and TTE provided the same diagnosis in 51/92 patients (55%)(Table 4). 
There was a moderate agreement between CMR and TTE with regards to IHD, 
which was confirmed on CMR in 22/26 patients (85%)(Cohen’s kappa 0.50), 
and to structurally normal heart, confirmed on CMR in 11/20 patients 
(55%)(Cohen’s kappa 0.43). There was a fair agreement with regards to NIHD, 
which was confirmed on CMR in 15/24 patients (63%)(Cohen’s kappa 0.21); 
based on tissue characterization CMR identified 7 patients with an ischemic 
distribution pattern of LGE. CMR provided a diagnosis in 14/22 (64%) patients 
with non-specific findings on TTE, identifying 6 patients with IHD and 8 patients 
with NIHD. The ability of CMR to be more definite regarding the underlying 






Table 4. Diagnostic agreement between CMR and TTE 
Boxes in bold represent patients receiving the same diagnosis based on both 
CMR and TTE findings. IHD, ischemic heart disease; NIHD, non-ischemic heart 
disease; SNH, structurally normal heart.  
 
Clinical impact of CMR 
CMR provided a clinical impact in 77/110 patients (70%), leading to change in 
diagnosis in 27 patients (25%), in management in 32 (29%), and both in 
diagnosis and management in 18 patients (16%). An entirely new diagnosis was 
found in 25% of patients, most commonly structurally normal heart (11%) and 
NIHD (10%). CMR led to an invasive procedure in 32 (29%) patients, namely 
myocardial revascularization in 21 (19%) and ICD implantation in 11 (10%). 
Based on CMR findings, an invasive procedure was avoided in 15 (14%) 
patients. CMR had greater clinical impact in SCAD patients with no culprit lesion 
(p=0.002), more frequently experiencing a change in management (86% vs. 
25% unobstructed coronaries, p<0.001); a change in diagnosis occurred more 
frequently among patients with unobstructed coronaries (58% vs. 8% SCAD 
patients, p<0.001).  
  CMR  






IHD 22 1 3 - 26 
NIHD 7 15 1 1 24 
Structurally Normal Heart 3 4 11 2 20 
Non-specific Findings 6 8 5 3 22 
 Total 38 28 20 6 92 
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3.5  Discussion 
 
The main findings of our study were that: 1) 2/3 of OHCA survivors referred to 
CMR have inconclusive findings on angiogram; 2) CMR identified a pathologic 
substrate in 69% of the population and a structurally normal heart in 23%; 3) 
CMR had a clinical impact in more than two thirds of patients. Acute coronary 
syndromes account for more than two thirds of OHCA (10,17,21,22) mainly 
secondary to acute coronary thrombosis or ruptured plaque (100,102) as 
confirmed by autopsy series. International guidelines recommend urgent 
angiography in OHCA survivors with STE (37) or whenever there is high 
suspicion of on-going infarction, irrespective of ECG (37). However, only a 
minority of cases (30–40%) shows angiographic and clinical evidence of ACS 
(37), a figure similar to that (37%) in our study. Causes other than acute 
ischemia are reported in up to 30% of cases. When acute ischemia is the 
obvious cause of OHCA, fewer patients are referred to CMR, mainly to assess 
the extent of myocardial scarring and the functional significance of bystander 
CAD. On the other hand, an inconclusive angiogram poses a diagnostic 
dilemma requiring further investigation, and to the best of our knowledge this is 
the first study looking at the role and clinical impact of CMR in OHCA survivors 
with this angiographic finding. Identifying OHCA aetiology is often challenging in 
the acute setting, as clinical data are often lacking and ECG and 
echocardiographic interpretation might be affected by resuscitation manoeuvres 
or external defibrillation (41)(100). However, correct identification of the under- 
lying cause, especially if reversible, plays a determinant role for appropriate 
treatment strategy and long-term prognosis. CMR has a well-established 
diagnostic role, both in the ischemic and non- ischemic scenario, based on its 
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superior tissue characterization properties. In our study, CMR could identify an 
underlying pathologic substrate in 69% of the population, as compared to 54% 
by TTE (p=0.018), and this was mainly due to LGE analysis. This superior 
diagnostic ability carried additional value and clinical impact over TEE in the 
management of these patients; for example, non-specific findings were more 
frequently reported by TTE (24% vs 8%), but CMR was able to identify a 
pathologic substrate in two thirds of them. We found a high prevalence of LGE 
among OHCA survivors (65%), in keeping with that recently reported by Neilan 
(71%) in OHCA survivors referred to CMR because of an unclear diagnosis 
(after clinical and diagnostic assessment) (49). The aim of their study was to 
identify the role of LGE as an arrhythmic substrate and as a predictor of 
adverse cardiovascular events. They found that LGE presence and extent are 
the strongest predictors of adverse arrhythmic outcome, further confirming the 
relationship between myocardial damage and major arrhythmias, and 
strengthening the association between tissue characterization and arrhythmic 
risk, independent of the ejection fraction, as reported by many studies on 
cardiovascular outcome (99). White et al. (48) showed that CMR-based imaging 
had a pick-up diagnostic rate of 74% in identifying the myocardial substrate of 
ventricular arrhythmias vs. 51% based on non-CMR imaging (i.e. diagnosis of 
MI missed in one third of patients on non-CMR imaging). In our study, CMR 
identified ischemic myocardial damage in 11 patients (15%) with unobstructed 
coronaries on angiogram; TTE diagnosed IHD in only one of them. Among 88 
patients with no label of prior MI, Neilan (49) found ischemic LGE in 49, thus 
supporting the hypothesis that the presence of LGE in patients with 
unobstructed coronaries identifies a subgroup of patients at increased risk of 
arrhythmic events. Compared to Neilan, our study explored the comparative 
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value of CMR vs TTE, as well as the clinical impact of CMR in this patients’ 
cohort. As already confirmed in different populations, such as in heart failure 
[26], we found that CMR changed both diagnosis and management in a 
considerable proportion of OHCA survivors (70%). Of interest, CMR showed a 
clinical impact both in patients with unobstructed coronaries, mainly by 
providing a change in diagnosis, and in SCAD patients with no culprit lesion, 
mainly by a change in management. An entirely new diagnosis was identified in 
25% of cases, mainly based on tissue characterization: a structurally normal 
heart was found in 11% of patients, based on the absence of LGE, and NIHD 
was diagnosed in 10%. Stress perfusion CMR has a well-established role not 
only in detecting CAD and guiding sub-sequent treatment strategy, but also in 
the identification of patients at increased risk of major adverse cardiovascular 
events (99). Stress perfusion CMR, performed in nearly half of SCAD patients 
with no culprit lesion, found inducible ischemia in 67% of patients, guiding 
myocardial revascularization in nearly all of them. It is well established that 
CMR has a role, over and above TTE, in re-classifying patients with regards to 
primary prevention ICD eligibility based on LVEF criteria, as it is the gold 
standard for LV function (57). The ability of CMR to detect reversible myocardial 
damage could play a role in guiding secondary prevention ICD implantation. In 
our patient population of OHCA survivors, CMR identified acute reversible 
myocardial injury (acute myocarditis and acute ischemia), thus avoiding 
secondary ICD implantation, as per guidelines, in 6% of patients. The main 
limitation of this study is the retrospective design. However, conducting a 
prospective trial in OHCA survivors might be difficult due to high mortality rate, 
variable downtime and consent. Sequences for myocardial oedema were 
available for analysis in half of the population, thus the clinical impact of 
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oedema analysis might have been higher if performed in all patients. A 
structurally “normal” heart by TTE and CMR reflects the absence of gross 
ischemic or non-ischemic underlying conditions, but it cannot exclude ultra-
structural abnormalities. Although endomyocardial biopsy is the gold standard 
to assess myocardial abnormalities, it is an invasive technique, not widely 
performed clinically and not performed in our patients; therefore some more 
subtle histological and cellular abnormalities cannot be excluded. With all the 
above limitations, this is a real world study that reflects clinical practice in most 
centres. Our study only analysed the presence of focal fibrosis, although it is 
increasingly evident that the presence of diffuse fibrosis has a prognostic role, 
detecting patients at higher risk of fatal arrhythmias. The use of the most recent 
T1 mapping technique might help further understand the pathologic substrate in 
this group of patients.  
 
3.6 Conclusions  
Although ACS account for the majority of OHCA, 63% of the survivors in our 
cohort had an inconclusive angiogram. CMR proved to be superior to TEE in 
the identification of a pathologic substrate for the event in this cohort (69% vs 
54%, p = 0.018) and its findings had a clinical impact in 70% of patients, 
providing a significant change both in diagnosis and in management. CMR 
showed a promising role in the clinical and diagnostic work-up of OHCA 
survivors with inconclusive angiogram and its wider use should be considered. 




Chapter 4. Aims 
 
Our preliminary study showed that CMR carries an additional role in the 
diagnostic process of OHCA survivors with no evidence of an acute ischemic 
cause on urgent angiogram, and that it has direct clinical implications in 
patients’ management and decision-making (99). This confirmed prior data 
showing that CMR is able to identify a structural substrate for OHCA in up to 
two thirds of patients, for whom an extensive clinical, electrocardiographic and 
echocardiographic assessment was not able to identify a diagnosis (46)(49). 
There is growing evidence of the prognostic role of CMR, especially in the 
setting of ventricular arrhythmias, which are characterised by a complex, 
multifactorial pathogenesis. Myocardial scarring has been shown to be a strong 
predictor of adverse outcome (death, ventricular arrhythmias, ICD discharge), 
both in the ischemic and non-ischemic setting (104)(105), and it has been 
shown to extend also over LV ejection fraction, which was long considered the 
key determinant of an unfavourable outcome. Less than 20% of patients 
experiencing SCD actually have severe left ventricular systolic dysfunction 
(LVEF ≤35%), and CMR studies have shown that a scar mass >5% in patients 
with LVEF>30% implies a higher risk of death and ICD discharge as compared 
to patients with LVEF≤30%, but with scar size <5% (106).  
Ventricular arrhythmias are the consequence of a trigger (i.e. acute ischemia, 
hypokalemia, etc.) superimposed to a favourable substrate, usually represented 
by inhomogeneous myocardial tissue, namely presence of viable myocites 
interspersed within fibrous tissue; recent CMR software allow the detection of 
infarct tissue heterogeneity (i.e. the scar itself and the peri-infarct zone), and 
different studies have shown that an increased tissue and scar heterogeneity 
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not only increases arrhythmias inducibility (107), but also increases 
susceptibility to ventricular arrhythmias in patients with impaired LV function 
(108)(109). More recently, the development of new CMR software that allow the 
analysis of myocardial deformation from cine images, with very limited post-
processing, have prompted the evaluation of CMR-derived myocardial strain as 
a predictor of adverse arrhythmic outcome. Myocardial strain not only has been 
shown to be a good predictor of adverse arrhythmic outcome in different 
cardiomyopathy groups, but has also shown to be a predictor of adverse 
outcome, irrespective of LVEF and LGE (110)(111).  
Among ventricular arrhythmias, the most severe and extreme form, leading to 
cardiac arrest, is ventricular fibrillation. It has been demonstrated that 
ventricular fibrillation, especially the idiopathic form (IVF), can recur in up to 
30% of cases (55), and this obviously carries important clinical implications on 
patients’ survival and quality of life, and on their clinical management. Being 
able to better stratify patients, who’ve already experienced OHCA, in order to 
offer the best and tailored treatment strategies, is very important. 
 
Aims of the study were: 
1) To assess a) the prevalence and extent of myocardial scar and b) 
myocardial deformation in VF cardiac arrest survivors 
2) To identify CMR-derived structural and mechanical predictors of 




Chapter 5. Materials and Methods  
 
We retrospectively analysed the CMR registry of the Bristol Heart Institute CMR 
centre (Bristol, United Kingdom) to enrol consecutive patients surviving a 
ventricular fibrillation out of hospital cardiac arrest. Patients were retrospectively 
followed-up to record a composite end-point of all-cause mortality, and 
appropriate ICD discharge or anti-tachycardia pacing (ATP) on VT or VF. 
Patients experiencing more than one end-point were only counted once: as the 
aim of the study was to identify structural and mechanical predictors of recurrent 
adverse events and given that the presence of myocardial scar is an 
established predictor of ventricular arrhythmias, in patients experiencing both 
ICD discharge and death, the ICD discharge was given more importance and 
counted as the only end-point. Mortality was assessed by electronic chart 
review; patients were followed-up at 3-6 month intervals via clinic/pacing visits. 
Duration of follow-up was determined from the date of the VF cardiac arrest, to 
the occurrence of the end-point. Patients’ follow-up was recorded by a clinician 
blinded to CMR findings. The study was reviewed by the local Institutional 
Research and Innovation Department and in view of the retrospective design of 
the study, formal ethical approval was waived off; the study was however 
approved as a service evaluation (SE102).  
 
5.1 CMR acquisition 
All patients were scanned in a 1.5T CMR scanner (Avanto, Siemens 
Healthcare, Germany), with a protocol comprehensive of long and short axis 
cine images, and post-contrast (LGE) images.  Steady state free precession 
sequences were performed to acquire the long and short axis cine images; 
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typical parameters were TR 38 ms, TE 1.07 ms, flip angle 80°, slice-thickness 8 
mm, inter-slice gap 0 mm, bandwidth 930 Hz/Px, voxel size 1.6x1.6x8.0 mm 
and temporal resolution ≤45 ms between phases. For LGE imaging, a standard 
inversion recovery gradient-echo sequence was adopted. The LGE images 
were acquired 10-15 minutes after intravenous injection of 0.1 mmol/Kg of body 
weight of gadolinium-chelate contrast agent (Gadovist 1.0 mmol/ml, Bayer-
Schering, Berlin, Germany) in identical short-axis planes to cine images, using 
an inversion recovery prepared breath-hold gradient-echo technique. Typical 
image parameters were TR 745 ms, TE 3.22 ms; flip angle 25°; slice thickness 
8.0 mm, no interslice gap, bandwidth 140 Hz/Px and voxel size 1.6 × 1.2 × 8.0 
mm. The inversion time was progressively optimized to null normal myocardium 
(typical values, 250–350 ms). Each slice was obtained during a breath-hold of 
10–15 s depending on the patient’s heart rate.  
 
5.2 CMR analysis 
Ventricular function was assessed with dedicated software (cvi42®, Circle 
Cardiovascular Imaging, Calgary, Canada), by tracing endo- and epicardial 
borders on each short axis cine slice in end-diastole and end-systole. All 
volumes measurements were indexed to body surface area.  
Myocardial deformation was assessed using the tissue tracking post-processing 
software (cvi42®, Circle Cardiovascular Imaging, Calgary, Canada), by 
contouring the left ventricular endocardial and epicardial border in two long-axis 
cine images (two and four chamber view) and in the short-axis cine stack (blood 
pool and papillary muscles excluded), with the initial contour set at end-diastole. 
Regional tissue tracking features in the three directions (longitudinal, radial and 
circumferential) were automatically computed on a 16 segment model and 
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averaged to provide global peak radial strain (GRS), global peak circumferential 
strain (GCS), and global peak longitudinal strain (GLS) (112). Accuracy of 
endocardial and epicardial contouring throughout the cardiac cycle was 
checked in order to ensure appropriate strain measurement (Figure 6). A single 
observer (A.B., European Association of Cardiovascular Imaging Level 3 
certified in Cardiovascular Magnetic Resonance) analysed all CMR data and 
intra-observer agreement was derived from the repetition of the analysis after 6 
months. The presence/absence, localization, and distribution pattern of LGE 
were assessed visually by using short- and long-axis views and defined as 
present only if detectable in two orthogonal planes; LGE distribution pattern was 
defined as subendocardial or transmural, if involving <50% or ≥50% of wall 
thickness, respectively, and as mid-wall/epicardial if patchy/spotty intra-mural or 
sub-epicardial enhancement was detected. The extent of LGE was quantified by 
using the full width at half maximum software (FWHM) (cvi42®, Circle 
Cardiovascular Imaging, Calgary, Canada), which uses half the maximal signal 
intensity within the scar as the threshold (65), and expressed as LGE mass, 
both in absolute terms (grams) and as percentage of the left ventricle. Ischemic 
heart disease (IHD) was defined as the presence of regional wall motion 
abnormality and subendocardial/transmural LGE consistent with coronary artery 
distribution territory; non-ischemic heart disease (NIHD) was defined as LGE 
with a mid-wall and/or epicardial pattern (59). A structurally normal heart (SNH) 
on CMR was defined as normal biventricular systolic function with no evidence 
of LGE. All the analysis was carried out in accordance with the recommendation 




Figure 6. Quality assessment during myocardial strain analysis. Once the 
endocardial and epicardial contours have been traced, the software tracks the 
same features throughout the cardiac cycle and derives strain measurement in 
the three directions (longitudinal, radial, and circumferential). The software 
displays boundaries points (A-C, endocardial and epicardial boundaries points 
in the 4 and 2 chamber, respectively) that can be followed throughout the 
cardiac cycle to check the accuracy of endocardial and epicardial contouring 
and ensure the accuracy of the derived strain measurements (B-D, global 
longitudinal strain in the 4 and 2 chamber, respectively).  
 
5.3 Statistical analysis 
Continuous and categorical variables are expressed as mean±SD or median 
(IQR), and n (%), respectively. Continuous data were compared by using the 2-
tailed unpaired t test (for normally distributed data sets) or by using the Mann-
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Whitney U test. Multiple comparisons were performed using the Kruskall-Wallis 
test. To assess intra-observer reliability of myocardial deformation analysis, 
myocardial strain assessment was performed by the same operator (A.B.) 6 
months after the first assessment on 29 randomly selected patients (24% of 
total population) and the intra-class correlation coefficient (ICC) was calculated. 
End-point predictors were tested at the univariate analysis and variables with a 
significant association with the end-point (p<0.05) were also tested in a 
multivariate model. Survival analysis was performed for the composite end-
point. A receiver-operating characteristic (ROC) curve was constructed to 
determine the optimal value with the maximum sensitivity and specificity for 
LGE extent as a predictor of adverse cardio-vascular events. A p-value of <0.05 
was considered statistically significant, unless when adjusted for multiple 
comparisons (Bonferroni correction, p<0.05/n, where n is the number of 
comparisons). Data were analysed in Stata (Stata v. 13, StataCorp, College 













Chapter 6. Results 
 
6.1 Clinical characteristics 
We consecutively enrolled 121 patients [82% male, 62 years (53-70)] surviving 
VF cardiac arrest. Approximately one third of patients had a history of 
hypertension (36%) and active smoking (27%), 21% of patients had 
hyperlipidemia, 14% were diabetic. The first ECG after ROSC, available in 107 
patients (88%), showed STE in 39 patients (36%) and NSTE in 68 (64%). All 
patients received an urgent angiogram on the day of admission: 74 patients 
(61%) had evidence of obstructive CAD, with a culprit lesion found in 50 
patients (41%); 47 patients (39%) had evidence of unobstructed coronary 
arteries. Clinical and demographic characteristics are summarized in Table 5.  
 




Gender, male 99 (82) 
Age, years 62 (53-70) 
Hypertension 43 (36) 
Diabetes 17 (14) 
Smoking 33 (27) 
Hyperlipidemia 25 (21) 
FHx CAD 9 (7) 
FHx SCD 1 (1) 
Previous CAD 26 (21) 
Findings on urgent  angiogram  
   - Non-obstructed Coronaries 47 (39) 
   - CAD 74 (61) 
   - Culprit identified 
   - PCI performed  
50 (41) 
42 (35) 
Therapy at discharge 
- Aspirin 
- P2Y12 inhibitors 







Values are expressed as n (%) and median (IQR). CAD, coronary artery 
disease; SCD, sudden cardiac death; ROSC, recovery of spontaneous 
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circulation; STE, ST elevation; NSTE, non-ST elevation; PPCI, primary 
percutaneous coronary intervention.  
 
6.2 CMR findings 
Cardiovascular magnetic resonance was performed within two weeks from 
OHCA [13 days (6-42)]. Left ventricular systolic function was overall mildly 
impaired and indexed volumes were mildly increased: LVEF 54% (IQR 41-
64%), LViEDV 89 ml/m2 (IQR 73-109 ml/m2), LViESV 42 ml/m2 (IQR 23-66 
ml/m2); 68 patients (56%) had evidence of regional left ventricular wall motion 
abnormality (WMA), while 12 (10%) had evidence of diffuse WMA. Right 
ventricular systolic function and indexed volumes were within normal range: 
RVEF 60% (IQR 53-65 %), RViEDV 72 ml/m2 (IQR 60-84 ml/m2), RViESV 28 
ml/m2 (IQR 21-39 ml/m2). On post-contrast images, LGE was found in 86 
patients (71%): an ischemic pattern was found in 75 patients (62%), with 
subendocardial and transmural extent in 36 and 39 patients, respectively; a 
non-ischemic pattern was noted in 11 patients (9%). No LGE was found in 35 
patients (29%). In a 16-segment model (excluding the apical cap), the median 
number of segments with LGE was 2 (IQR 0-6). Scar quantification showed a 
median scar mass of 3.8 grams (IQR 0-11 grams) (mean 7.8±10.8 grams), 
corresponding to 6.2 % (IQR 0-15%) of the left ventricle (mean LGE mass 
10.7±13.4% of the left ventricle). Ischemic heart disease was diagnosed on 
CMR in 75 patients (62%) and NIHD in 20 (17%); a structurally normal heart 
(SNH) was reported in 26 patients (21%). Among patients with NIHD, the most 
common diagnoses were DCM (n=5) and myocarditis (n=5), followed by HCM 
(n=3), TTC (n=2), ARVC (n=2), left ventricular non compaction (n=1), 
hypertensive heart disease (n=1), mitral valve prolapse (n=1). Patients with IHD 
 64 
had bigger left ventricular volumes and lower systolic function (p<0.001), while 
there was no difference in right ventricular volumes and function between IHD, 
NIHD and SNH. Myocardial LGE extent was significantly greater in IHD as 
compared to NIHD patients, both in terms of LGE mass (10.6% vs 1.6%, 
p<0.001) and number of myocardial segments affected by LGE (5 vs 0.5, 
p<0.001). Myocardial deformation was overall impaired: GLS -15.5 % (IQR -
18.9-  -12.3 %), GRS 34.2 % (IQR 25.2-45.2 %), GCS -15.5 % (IQR -20.3- -11.9 
%). Myocardial strain differed significantly between IHD, NIHD and SNH 
patients (p<0.001 for all myocardial strain components). Circumferential and 
radial myocardial strain was more impaired in IHD patients, while longitudinal 
strain was more impaired in NIHD patients. Intra-observer variability for 
myocardial deformation assessment was tested on 29 patients and showed 
excellent agreement for all myocardial strain components: GLS ICC=0.92 (95% 
CI 0-82-0.96), GRS ICC=0.94 (95% CI 0.87-0.97), GCS ICC=0.85 (95% CI 
0.70-0.93). CMR findings are summarised in Table 6.   
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Age, years 62 (53-70) 65 (57-71) 55 (41-68) 53 (41-63) 0.003 
Days to CMR 13 (6-42) 18 (7-55) 8 (6-11) 15 (5-42) 0.014 
LViEDV, ml/m2 89 (73-109) 95 (81-118) 92 (84-105) 76 (63-89) <0.001 
LViESV, ml/m2 42 (27-66) 48 (35-78) 42 (33-55) 27 (19-35) <0.001 
LVEF, % 54 (41-64) 47 (35-60) 55 (43-67) 64 (62-69) <0.001 
LV mass, g/m2 66 (55-82) 69 (59-84) 69 (56-83) 56 (48-66) 0.003 
RViEDV, ml/m2 72 (60-84) 66 (59-82) 76 (52-98) 76 (67-86) 0.232 
RViESV, ml/m2 28 (21-39) 27 (21-40) 31 (25-39) 29 (21-37) 0.435 
RVEF, % 60 (53-65) 59 (51-65) 61 (50-66) 60 (57-66) 0.235 
LGE 86 (71) 75 (100) 11 (55) 0 <0.001 
LGE mass, g 3.8 (0-11) 7.5  (3.5-17.35) 1.2 (0-6.0) 0 <0.001 
LGE mass, % 6.2 (0-15) 10.6 (5.6-21.9) 1.6 (0-9.5) 0 <0.001 
Segm. with LGE 2 (0-6) 5  (2-8) 0.5 (0-2) 0 <0.001 
GLS, % -15.5 (-18.9 -12.32) -14.7 (-18.2 -11.9) -13.3 (-18.2 -7.9) -18.6 (-22.2 -15.8) <0.001 
GRS, % 34.2 (25.2-45.2) 27.9 (21.8-39.1) 35.9 (25.2-45.9) 44.6 (36.8-53.2) <0.001 
GCS, % -15.5 (-20.33 -11.9) -13.6 (-18.4 -10.9) -14.9 (-20.7 -10.5) -20.4 (-22.9 -18.1) <0.001 
Values are expressed as n (%) and median (IQR). IHD, ischemic heart disease; 
NIHD, non-ischemic heart disease; SNH, structurally normal heart; LViEDV, 
indexed left ventricular end-diastolic volume; LViESV, indexed left ventricular 
end-systolic volumes; LVEF, left ventricular ejection fraction; RViEDV, indexed 
right ventricular end-diastolic volume; RViESV, indexed left ventricular end-
systolic volume; RVEF, right ventricular ejection fraction; LGE, late gadolinium 
enhancement; GLS, global longitudinal strain; GRS, global radial strain; GCS, 
global circumferential strain. Significant p-value after Bonferroni correction was 
0.017.  
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There was a linear correlation between all myocardial strain components and 
both the presence of LGE, the number of segments affected by LGE and LGE 
extent (% of LV) (Table 7 and Figure 7). 
 
Table 7. Correlation between LGE and myocardial deformation 
 LGE presence Segm with LGE LGE mass (% of LV) 
 B Coeff p-value 95% CI B Coeff p-value 95% CI B Coeff p-value 95% CI 
GLS 2.56 0.012 0.57-4.56 0.63 <0.001 0.43-0.84 0.14 <0.001 0.07-0.20 
GRS -9.20 0.001 -14.3- -4.1 -1.91 <0.001 -2.43- -1.39 -0.40 <0.001 -0.57- -0.23 
GCS 3.70 0.001 1.63-5.77 0.75 <0.001 0.53-0.96 0.19 <0.001 0.14-0.26 
LGE, late gadolinium enhancement; GLS, global longitudinal strain; GRS, global 
radial strain; GCS, global circumferential strain. 
 
 
Figure 7. 3D representation of longitudinal myocardial strain (A) showing an 
area of impaired strain in the mid-cavity to apical anterior wall (displayed in 
yellow), corresponding to an area of extensive LGE of the mid-cavity to apical 
anterior wall in a patient with ischemic heart disease (B, normal myocardium is 
displayed in green, LGE is displayed in yellow/black).  
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6.3 Patients with structurally normal heart on CMR 
Amongst patients with structurally normal heart on CMR, 6 underwent Ajmaline 
test, which allowed a diagnosis of Brugada syndrome in 2 patients. Three 
patients underwent exercise test to exclude cathecolaminergic polymorphic 
ventricular tachycardia, which was ruled out in all. Wolf-Parkinson-Whyte 
syndrome was diagnosed in 2 patients based on resting ECG, and one patient 
had ECG findings consistent with early repolarisation syndrome.  
Patients with structurally normal heart on CMR were matched with 26 healthy 
volunteers, of same age, gender and LVEF (all factors known to affect 
myocardial strain). There was no difference in myocardial deformation between 
VF cardiac arrest survivors and healthy controls matched for age, gender and 
LVEF: GLS -18.6% vs -19.9% (p=0.249), GRS 44.6% vs 42.4% (p=0.51), GCS -
20.4% vs -21.0% (p=0.661). 
 
6.4 Outcome  
Outcome data were available in 99 patients (82%). Twenty-two patients (18%) 
were lost to follow-up, as they were referred to CMR in our centre from district 
hospitals, but were not taken care of by our local Clinical Care Team. Median 
follow-up was 24 months (IQR 6-41 months). Fifty-two patients (52%) were 
implanted with an ICD as secondary prevention, and they were followed-up at 
3-6 months interval at the local outpatient pacing clinic; the median number of 
pacing clinic visits (in order to obtain regular ICD interrogation) was 8 (IQR 5-
11). The composite end-point was met in 24 patients (24%): 14 patients had 
appropriate ICD discharge/ATP (6 had multiple appropriate shocks for recurrent 
VF episodes; 4 patients died) and 10 patients died; all but one death was of 
cardiac origin. The median time from VF cardiac arrest to the first end-point was 
 68 
18 months (IQR 3-25 months). There was no difference in clinical and 
demographic characteristics of patients meeting and not meeting the end-point 
(Table 8), and therapy at discharge did not differ between the two groups 
(aspirin p=0.174; P2Y12 inhibitors p=0.905; ACE inhibitors p=0.982; beta-
blockers p=0.432). Amongst patients meeting the end-point, 15 were found to 
have IHD on CMR, 5 had NIHD and 4 had SNH. Patients meeting the end-point 
had bigger LV volumes (LViEDV 111 ml/m2 vs 89 ml/m2, p=0.006, LViESV 66 
ml/m2 vs 40 ml/m2, p=0.039), but similar LVEF as compared to patients not 
meeting the end-point (45% vs 40%, p=0.128); when considering LVEF, 7 
patients experiencing recurrent adverse events had LVEF≤35%, while 17 
patients experiencing recurrent adverse events had LVEF>35%. Right 
ventricular ejection fraction was significantly lower in patients meeting the end-
point (58% vs 61%, p=0.03). Late gadolinium enhancement was more 
commonly seen in patients meeting the end-point (83% vs 64%), but without 
reaching statistical significance (p=0.075). Four adverse events occurred in 
patients with no evidence of LGE on CMR, as opposed to 20 adverse events 
occurring in patients found to have LGE on CMR; no death occurred in the LGE 
negative group, and all recurrent events consisted of successful ATP on VT 
(n=3), and ICD shock on VF (n=1). In the LGE positive group, 10 patients 
experienced appropriate ICD discharge (9 patients had appropriate shock on 
VT, 1 had ATP on VT) and 10 patients died; of the 10 patients with appropriate 
ICD discharge, 4 died later on during follow-up. Extent of LGE was significantly 
greater in patients meeting the end-point (8.6% vs 4.1%, p=0.022), which also 
had a significantly higher number of myocardial segments affected by LGE (4 vs 
2, p=0.041). There was no difference in myocardial deformation between 
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patients with and without the end-point (GLS p=0.369, GRS p=0.498, GCS 
p=0.319).  
 






Gender, male 22 (92) 60 (80) 0.187 
Age, years 67 (53-74) 62 (53-69) 0.270 
Hypertension 12 (50) 27 (36) 0.222 
Diabetes 5 (21) 10 (13) 0.372 
Smoking 8 (33) 20 (27) 0.528 
Previous CAD 6 (25) 9 (12) 0.122 
LViEDV, ml/m2 111 (86-135) 89 (71-105) 0.006 
LViESV, ml/m2 66 (34-84) 40 (25-53) 0.039 
LVEF, % 40 (25-53) 45 (31-64) 0.128 
LV mass, g/m2 70 (57-98) 63 (53-80) 0.104 
RViEDV, ml/m2 77 (62-96) 69 (60-85) 0.259 
RViESV, ml/m2 35 (25-41) 26 (21-37) 0.037 
RVEF, % 58 (49-63) 61 (55-66) 0.030 
LGE 20 (83) 48 (64) 0.075 
LGE mass, g 7.3 (3.9-16.7) 2.5 (0-8.8) 0.008 
LGE mass, % 8.6 (4.4-28.2) 4.1 (0-13.8) 0.022 
Segm. with LGE 4 (2-8) 2 (0-5) 0.041 
Transmural LGE 0 (0-3) 0 (0) 0.126 
GLS, % -12.9 (-20.9- -9.8) -15.9 (-18.7- -12.8) 0.369 
GRS, % 29.5 (21.2-47.1) 34.4 (25.8-44.7) 0.498 
GCS, % -14.1 (-20.4- -10.1) -16.6 (-20.6- -12.5) 0.319 
Values are expressed as n (%) and median (IQR). CAD, coronary artery 
disease; LViEDV, indexed left ventricular end-diastolic volume; LViESV, 
indexed left ventricular end-systolic volumes; LVEF, left ventricular ejection 
fraction; RViEDV, indexed right ventricular end-diastolic volume; RViESV, 
indexed left ventricular end-systolic volume; RVEF, right ventricular ejection 
fraction;  LGE, late gadolinium enhancement; GLS, global longitudinal strain; 
GRS, global radial strain; GCS, global circumferential strain. 
 
The following variables were tested on univariate analysis as predictors of 
recurrent adverse events: LV volumes and systolic function, RV systolic 
function, presence and extent of LGE and myocardial deformation (GLS, GRS 
 70 
and GCS). Associations with a p-value <0.05 were included in a multivariate 
model.  Variables associated with adverse outcome on univariate analysis were 
LV volumes (LViEDV p=0.009; LViESV p=0.010), RVEF (p=0.044) and LGE 
mass (% of the LV)(p=0.013). In a multivariate model, LGE extent was the only 
variable retaining a trend towards an association with adverse outcome, 
although statistical significance was not reached (p=0.059) (Table 9).  
 
 
Table 9. Predictors of recurrent adverse events 
 Univariate Multivariate 
 B Coeff p-value 95%CI B Coeff p-value 95%CI 
LViEDV 0.02 0.009 0.005-0.03 0.02 0.263 -0.02-0.06 
LViESV 0.02 0.010 0.004-0.03 -0.01 0.595 -0.05-0.03 
LVEF -0.03 0.090 -0.06-0.004 - - - 
RVEF -0.05 0.044 -0.10- -0.001 -0.03 0.261 -0.09-0.02 
LGE 1.03 0.084 -0.14-2.21 - - - 
Segm. with LGE 0.10 0.068 -0.008-0.214 - - - 
LGE mass, % 0.05 0.013 0.009-0.08 0.04 0.059 -0.002-0.08 
GLS 0.03 0.492 -0.55-0.12 - - - 
GRS -0.01 0.478 -0.05-0.02 - - - 
GCS 0.05 0.292 -0.04-0.13 - - - 
Associations with a p-value <0.05 on univariate analysis were tested on a 
multivariate model. LViEDV, indexed left ventricular end-diastolic volume; 
LViESV, indexed left ventricular end-systolic volumes; LVEF, left ventricular 
ejection fraction; RViEDV, indexed right ventricular end-diastolic volume; 
RViESV, indexed left ventricular end-systolic volume; RVEF, right ventricular 
ejection fraction;  LGE, late gadolinium enhancement; GLS, global longitudinal 
strain; GRS, global radial strain; GCS, global circumferential strain. 
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A ROC curve was created to determine what LGE extent could help identify a 
group of patients, among those with LGE, at increased risk of adverse events. 
ROC curve analysis showed that LGE mass of 4.3% of the LV could yield 
maximum values of sensitivity and specificity to predict adverse events (area 
under the curve 0.65; sensitivity 75%; specificity 53%) (Figure 8).  
 
 
Figure 8. Receiver-operating curve (ROC) testing LGE mass (% of LV) as a 
predictor of recurrent adverse events. Analysis revealed that LGE mass ≥4.3% 
of LV provided the maximal combination of sensitivity and specificity.  
 
Kaplan-Meier curves were created for event-free survival using both LGE 
presence/absence and LGE extent (% of LV, cut-off value of >4.3%) (Figure 9). 
Patients with LGE extent >4.3% of the LV were found to represent a subgroup 
at higher risk of recurrent adverse events (p=0.0048): 18 adverse events were 
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encountered among patients with LGE extent >4.3%, as compared to 6 adverse 
events among patients with LGE extent <4.3% of LV.  
 
 
Figure 9. Kaplan-Meier curves displaying event-free survival according to 
presence/absence of LGE and according to LGE cut-off >4.3%.  
 
6.5 Outcome in patients wearing ICD 
Fifty-two patients (52%) were implanted with an ICD for secondary prevention. 
Patients implanted with an ICD tended to be younger, although the difference 
was not statistically significant (58 years vs 63 years, p=0.06). There was no 
difference in biventricular volumes (LViEDV 91 ml/m2 vs 92 ml/m2, p=0.486, 
LViESV 42 ml/m2 vs 39 ml/m2, p=0.260; RViEDV 73 ml/m2 vs 70 ml/m2, 
p=0.232, RViESV 28 ml/m2 vs 28 ml/m2, p=0.525) and function (LVEF 50% vs 
58% p=0.122, RVEF 60% vs 60%, p=0.981) between patients who received or 
did not receive an ICD; there was also no difference in LGE extent (5.5% of LV 
vs 6.2%, p=0.369). Myocardial strain was more impaired in patients who 
received an ICD (GLS -13.3% vs -17.3, p=0.003; GRS 27.5% vs 36.9%, 
p=0.017; GCS -13.2% vs -16.9%, p=0.028). Among patients implanted with an 
ICD, 16 met the end-point (31%). Left ventricular volumes and function did not 
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differ between patients meeting or not meeting the end-point (Table 10), while 
RViESV (36 ml/m2 vs 25 ml/m2, p=0.022) and RVEF (55% vs 61%, p=0.024) 
were respectively bigger and lower in patients meeting the end-point. There was 
a trend towards a higher prevalence of LGE amongst patients meeting the end-
point, but statistical significance was not reached (75% vs 50%, p=0.092). Only 
one patient had an inappropriate shock on atrial tachycardia; 4 ICDs were 
extracted and replaced (3 secondary to pocket infection and 1 secondary to 
malfunction) and 4 patients needed atrial or ventricular lead replacement 
secondary to dislodgement.  
 






LViEDV, ml/m2 98 (76-141) 91 (76-108) 0.201 
LViESV, ml/m2 39 (27-96) 42 (29-63) 0.565 
LVEF, % 50 (32-68) 52 (37-64) 0.889 
LV mass, g/m2 80 (52-98) 70 (58-84) 0.471 
RViEDV, ml/m2 75 (60-109) 63 (53-85) 0.273 
RViESV, ml/m2 36 (24-52) 25 (18-36) 0.022 
RVEF, % 55 (48-63) 61 (53-70) 0.024 
LGE 12 (75) 18 (50) 0.092 
LGE mass, g 5.4 (0.9-12.1) 0.7 (0-11.6) 0.187 
LGE mass, % 6.9 (0.9-12.8) 0.9 (0-15.4) 0.224 
Segm. with LGE 3 (0.3-5) 0.8 (0-6.3) 0.193 
GLS, % -13.8 (-21.3- -9.3) -13.5 (-18.6- -11.4) 1.000 
GRS, % 30 (18.4-47.1) 27.5 (18.6-45.3) 0.937 
GCS, % -15 (-21.9- -10.6) -13.2 (-20.3- -10.5) 0.677 
Values are expressed as n (%) and median (IQR). LViEDV, indexed left 
ventricular end-diastolic volume; LViESV, indexed left ventricular end-systolic 
volumes; LVEF, left ventricular ejection fraction; RViEDV, indexed right 
ventricular end-diastolic volume; RViESV, indexed left ventricular end-systolic 
volume; RVEF, right ventricular ejection fraction;  LGE, late gadolinium 
enhancement; GLS, global longitudinal strain; GRS, global radial strain; GCS, 
global circumferential strain. 
 
 74 
Chapter 7. Discussion  
 
The main findings of this study were that in VF cardiac arrest survivors 1) there 
is a high prevalence of LGE (71%), mainly with an ischemic pattern, 2) 
myocardial deformation is overall impaired, despite an only mildly impaired 
LVEF (54%), 3) there is no difference in LVEF between patients meeting the 
end-point and those event-free, 4) LGE extent, rather than its presence, is 
associated with a worse outcome, while 5) myocardial deformation is not a 
predictor of adverse recurrent events.  
 
7.1 Late gadolinium enhancement  
In a cohort of VF cardiac arrest survivors undergoing CMR, we found a high 
prevalence of LGE (71% of patients), mainly presenting with an ischemic 
distribution pattern (87% of all patients with LGE), confirming that the leading 
cause of cardiac arrest is ischemic (17). These findings are in keeping with 
previous data from Neilan et al. in a similar cohort of VF/VT cardiac arrest 
survivors, which showed on CMR a 71% prevalence of LGE with an ischemic 
pattern in 68% of patients (49). The presence and distribution pattern of LGE in 
our cohort led to the identification of a pathological substrate of the cardiac 
arrest in 79% of patients, which is very similar to the 76% reported by Neilan et 
al. (49). There is increasing evidence of the additional diagnostic role of CMR in 
cardiac arrest survivors, which comes from the superior ability of CMR to 
provide myocardial tissue characterisation. White et al. performed CMR in 82 
cardiac arrest survivors which received routine non-CMR imaging and found 
that CMR was able to identify an underlying cause in 74% of patients as 
opposed to 51% provided by non-CMR imaging, and that nearly half of patients 
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where re-classified to a different diagnosis based on CMR (48). Similarly, in our 
previous study, we found that among cardiac arrest survivors with no evidence 
of an acute ischemic cause on angiogram (stable obstructive CAD with no 
culprit lesion or unobstructed coronaries), CMR was able to identify an 
underlying pathological substrate in 69% of the population, as compared to 54% 
as provided by trans-thoracic echocardiogram (TTE)(99); moreover, CMR was 
able to identify a pathological substrate in more than two thirds of patients with 
non-specific findings on TTE. We found that median LGE mass in our cohort of 
VF cardiac arrest survivors was 6.2% of LV myocardium (mean 10.7±13.4%), 
which was comparable to that reported by Neilan et al. (9.9±5% of LV 
myocardium).  The association between myocardial scarring and ventricular 
arrhythmias has been extensively described, both in ischemic and non-ischemic 
cardiomyopathies (61)(109). In post-MI patients undergoing CMR prior to ICD 
implantation, scar extent was the strongest predictor of arrhythmic events (SCD, 
ICD discharge, ventricular arrhythmias) irrespective of LVEF (113)(114); Klem 
et al. have also shown that among patients undergoing evaluation of possible 
ICD implantation, those with LGE extent >5% and LVEF>30% had a higher risk 
of arrhythmic events than patients with LVEF ≤30% but LGE extent <5% (115). 
On the other hand, among 300 patients with sustained and non-sustained VT 
undergoing CMR, those with LGE had higher risk of cardiac death/arrest, new 
VT episodes or appropriate ICD discharge; while LGE extent was the only 
predictor of recurrent events among patients with non-sustained VT, both LGE 
extent and reduced LVEF predicted recurrent events among patients with 
sustained VT (116). Most of studies assessing the role of LGE as predictor of 
adverse outcome were limited by small sample size and low number of events. 
A recent meta-analysis (117) on nearly 3000 patients, with both ischemic and 
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non-ischemic cardiomyopathies, confirmed the prognostic role of LGE, both in 
terms of presence/absence and extent (mass), which appears to be even 
superior in patients having a reduced LVEF (odds ratio doubles in patients with 
LVEF≤30% as compared to patients with LVEF>30%).  
 
7.2 Myocardial strain 
Myocardial deformation in our cohort was overall impaired, despite an only 
mildly impaired LVEF (median 54%), but it is well-recognised that myocardial 
strain is an early marker of disease and that it is often impaired before a 
reduction in LVEF is noted (89)(90). We found a significant difference in all 
myocardial strain components according to CMR findings (IHD, NIHD and 
structurally normal heart) (p<0.001). Interestingly, while GCS and GRS were 
more impaired among IHD patients, GLS was more impaired in NIHD patients. 
Global longitudinal strain is believed to be more sensitive to acute injury, as 
compared to GCS and GRS; NIHD patients underwent CMR earlier compared 
to IHD patients (time to CMR 8 days vs 18 days in IHD patients), and the more 
severe impairment of GLS could be a consequence of earlier CMR imaging 
detecting more acute injury (118). The difference in myocardial deformation 
between patients with IHD, NIHD and SNH is likely a consequence of the 
presence of myocardial LGE: we’ve found a linear correlation between all strain 
components and both the presence and extent of LGE (both as number of 
myocardial segments with LGE and LGE mass as percentage of LV 
myocardium, p<0.001 for both). A correlation between myocardial strain and 
myocardial LGE has been previously described, both in ischemic and non-
ischemic cardiomyopathies. Myocardial deformation allows the differentiation of 
normal myocardial segments from segments with subendocardial and 
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transmural LGE, not only as absolute, global values, but also in the sub-
analysis of endocardial and epicardial strain values, which both decrease with 
increasing degrees of MI extent (91). A significant difference in peak 
circumferential strain has been described between infarcted, remote and 
adjacent myocardial segments, and between remote and adjacent segments 
right after an acute MI, and at follow-up (95)(119). Similar findings have been 
described in NIHD: Mordi et al. found a correlation between the percentage of 
LGE and global circumferential strain, as assessed by CMR tagging, in a cohort 
of more than 500 patients referred for a clinically indicated CMR (most of 
patients were referred for stratification of suspected heart failure)(111). 
Similarly, a combined protocol, comprehensive of SpTE and LGE on CMR, 
studying DCM patients, found LGE in 56% and impairment of all myocardial 
strain components: there was a significant difference in myocardial deformation 
between patients with and without LGE (119). Interestingly, we found no 
difference in myocardial strain between VF cardiac arrest survivors with 
structurally normal heart on CMR and a control group of healthy volunteers, 
matched for age, gender and LVEF (known factors influencing myocardial 
strain). This finding differs from a recently reported reduction in 3D peak strain 
in patients with ventricular arrhythmias (premature ventricular beats, non-
sustained VT or arrhythmias detected during catheter 
ablation/electrophysiologic study) and a structurally normal heart (120); the 
Authors, however, provided the segmental peak strain assessment and 
reported a correlation between regional variations in myocardial strain and 




7.3 Predictors of recurrent adverse events 
Patients surviving cardiac arrest are at higher risk of recurrent adverse events, 
such as death and ICD discharge for recurrent ventricular arrhythmias. Among 
more than 2000 patients implanted with an ICD for primary (61%; mean LVEF 
29%) or secondary prevention (39%; mean LVEF 37%), those treated for 
secondary prevention had a 74% increased risk of appropriate ICD therapy 
(51% 5-year incidence vs 37% in primary prevention)(121), although the long-
term risk for all-cause mortality was comparable between the two groups. A 
study on post-MI cardiac arrest survivors (n=48), which were matched with 
cardiac arrest survivors without MI (n=48) and MI patients without cardiac arrest 
(n=96), showed a 67% 5-year end-point-free survival (end-point: death/recurrent 
ventricular arrhythmias) among post-MI cardiac arrest survivors, which was 
significantly lower compared to cardiac arrest survivors without MI (80%) and MI 
patients without cardiac arrest (92%)(122); it should be noted, however, that 
mean LVEF in the different groups was 34%. During a median follow-up of 24 
months the composite end-point of death or appropriate ICD discharge/ATP in 
our cohort was 24%. The current practice in the centre where this study was 
conducted is in favour of programming the ICD in order to reduce shocks, so 
that arrhythmia detection interval is increased to allow self-termination of 
arrhythmias; this might explain the lower incidence of ICD discharge in our 
cohort as compared to the study by Neilan et al. (34% ICD discharge). Median 
LVEF in our cohort (54%) was higher than that reported in other studies 
assessing recurrent events after a first episode of cardiac arrest, so that the 
lower incidence of recurrent events in our cohort might in part be explained by a 
better functional class. There was however no difference in LVEF between 
patients experiencing adverse recurrent events and those with a more 
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favourable outcome (40% vs 45%, p=0.128). Left ventricular ejection fraction is 
increasingly recognised as an unsatisfactory prognostic marker (115) and in our 
cohort 7 patients meeting the end-point had LVEF≤35%, while the remaining 17 
patients meeting the end-point had LVEF>35%, which means they wouldn’t 
have even fallen into the group of patients eligible to receive an ICD as primary 
prevention. In a multi-centre study on more than 1000 patients undergoing 
assessment of LVEF and scarring on CMR both a reduced LVEF (mean LVEF 
in the population was 45±18%) and the presence of myocardial segments with 
LGE were independent predictors of mortality; however, in patients with mildly 
impaired LVEF (≥50%), those with >4 myocardial segments with LGE had 
worse outcome than those with less myocardial segments with LGE (p=0.02) 
(123). We found that the prevalence of LGE was higher in patients experiencing 
recurrent adverse events, although it did not reach statistical significance (LGE 
was found in 83% of patients meeting the end-point vs 64% of patients not 
meeting the end-point, p=0.075). However, LGE extent, both in terms of number 
of segments with LGE (p=0.041) and LGE mass as percentage of LV 
myocardium (p=0.022) were significantly higher in patients meeting the end-
point. Interestingly we found that transmural LGE extension did not differ 
between patients with and without adverse outcome [0 (0-3) vs 0 (0), p=0.126]. 
This likely suggests that not only the absolute amount of LGE, but also the 
number of myocardial segments involved by LGE, are important prognostic 
factors, more than the presence of LGE or its locally transmural extent. When 
considering the ROC curve analysis for LGE extent, we found an AUC of 0.65 
(SE 0.06, 95% CI 0.53-0.78), with a cut-off of 4.3% of LV myocardium 
maximising the best sensitivity and specificity for prediction of recurrent events 
(p=0.0048); this is lower than the 8.1% of LV myocardium reported by Neilan et 
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al. in a similar population of VT/VF cardiac arrest survivors (49), but similar to 
the 5% reported by Klem et al. in a population referred to CMR for evaluation of 
ICD implantation (115). Chimura et al. (119) combined SpTE for strain 
assessment and LGE CMR to assess patients with DCM for a composite end-
point of cardiac death, re-hospitalisation for HF and cardiac transplantation 
(SCD and ventricular arrhythmias were included among the secondary end-
points): despite a strong correlation between all myocardial strain components 
and LGE, only GLS (but not GRS or GCS) and LGE were independent 
predictors of worse outcome. Having a normal GLS was a predictor of better 
outcome, also irrespective of the presence of LGE. Similar to our findings, 
LVEF, which was overall severely impaired (mean LVEF of 33%) in their cohort, 
did not prove to be a predictor of adverse outcome. Another study assessing 
myocardial strain with CMR followed-up for 5 years 210 DCM patients with 
reduced LVEF (mean 36%); patients with worse outcome (SCD, ICD discharge) 
had a trend towards a higher prevalence of LGE (51% vs 34%, p=0.07) and 
significantly more impaired myocardial deformation in all three directions. All 
myocardial strain components were predictors of adverse outcome and GLS 
was an independent predictor of adverse outcome irrespective of both LVEF 
and the presence of LGE (110). Another study performed with CMR tagging on 
more than 500 patients referred for clinically indicated CMR found that LVEF, 
LGE and GCS were independent predictors of all-cause mortality, aborted SCD 
and hospitalisation for heart failure; interestingly, patients with LVEF >35% with 
LGE and impaired GCS had worse outcome than those with LVEF <35% (111). 
We found no difference in myocardial deformation between patients with and 
without adverse outcome, even when considering only patients implanted with 
an ICD. Many echocardiographic and CMR studies described a correlation 
 81 
between impaired myocardial deformation and adverse outcome: there is 
however a wide heterogeneity in populations studied (ischemic and non-
ischemic), none of whom resembles our population of cardiac arrest survivors, 
and an even wider heterogeneity in their methods (SpTE vs CMR derived strain, 
CMR-derived strain based on different vendors). Finally, in most of these 
studies mean LVEF was severely impaired, describing populations with 
advanced heart failure and functional class impairment; in our population LVEF 
was only mildly impaired (median 54%) and this might explain why myocardial 
deformation was not able to risk stratify patients. In order to identify predictors 
of adverse outcome, we tested biventricular volumes and function, LGE 
presence and extent and myocardial deformation on univariate analysis; only 
left ventricular volumes, right ventricular ejection fraction and LGE extent as % 
of LV myocardium showed a significant association on univariate analysis 
(p<0.05) and were tested on multivariate analysis. Only LGE extent as % of LV 
myocardium showed an association with outcome, although the p-value was 
borderline significant (p=0.059). In a similar cohort of VT/VF patients followed-
up for all-cause mortality and appropriate ICD intervention, LGE extent proved 
to be the strongest predictor of events, among different demographic (age, 






Our study has some limitations. First of all, we only have data on VF cardiac 
arrest survivors referred to CMR and not on those surviving a cardiac arrest that 
were not referred to CMR; VF cardiac arrest survivors were referred to CMR at 
the discretion of the clinical care team, and this might represent a selection 
bias, but at the same time it represents real world practice of a high volume, 
third level Cardiovascular centre. The range of normal strain values is quite 
wide, both as a consequence of age, gender and heart rate related variations 
(78)(80), but mainly secondary to the different studies that have assessed strain 
normality in different populations and using different vendors(124); intra and 
inter-observer variability also vary considerably in different studies (80). To 
reduce strain analysis variability in our study, only one experienced observer 
assessed myocardial deformation and repeated measurements on 29 randomly 
selected patients, six months after the first assessment; moreover, global strain 
assessment was preferred over segmental analysis, as this is known to be less 
robust and less reproducible (80)(78): this resulted in excellent intra-observer 
agreement for all three myocardial strain components (ICC=0.92 for GLS, 
ICC=0.94 for GRS and ICC=0.85 for GCS). Time to CMR differed significantly 
between groups, mainly based on clinician’s discretion: it is recognised that the 
earlier performance of CMR increases the chances to detect myocardial 
oedema, thus increasing the diagnostic capability of the imaging technique. 
However, myocardial oedema sequences were not systematically performed in 
our patient’s cohort, so that we cannot exclude the concomitant presence of 
myocardial oedema, which, according to recent evidence from 
echocardiographic studies in Tako-Tsubo cardiomyopathy (125)(126), might in 
part have contributed to myocardial strain impairment. We did not systematically 
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perform T1 mapping in our cohort; there is growing evidence that diffuse, rather 
than focal, myocardial fibrosis, as assessed by the novel T1 mapping technique, 
stratifies IHD and NIHD patients according to their arrhythmic risk (127), thus 
improving selection of primary prevention ICD implantation. Systematic 
inclusion of the T1 mapping technique might be useful in stratification of 
recurrences after VF cardiac arrest, and its role should be assessed with 
powered studies. Finally, outcome data were collected retrospectively and 
patients not currently followed-up at our Institution might have met the end-point 
after being lost to follow-up, which could not be accounted for.  
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Chapter 8. Conclusion 
 
Cardiovascular magnetic resonance has proved to be an important diagnostic 
tool in patients surviving out of hospital cardiac arrest, identifying a pathological 
substrate of the VF cardiac arrest in 79% of cases. While CMR-derived LVEF 
and myocardial strain assessment was not able to detect patients at an 
increased risk of adverse events, an LGE extent >4.3% of LV myocardium 
identified a subgroup of patients at higher risk of adverse events.  
 
8.1 Future directions  
Cardiovascular magnetic resonance has emerged as an important diagnostic 
tool and prognostic predictor in different cardiomyopathy groups, but further 
studies, on larger populations, are warranted in order to confirm and expand the 
role of CMR as a risk stratification tool in patients surviving cardiac arrest. The 
latest mapping sequences (T1 and T2 mapping), which provide a detailed 
characterisation of how the myocardial tissue and the interstitial space interact 
with each other, may allow a better delineation of the complex pathological 
mechanism behind ventricular arrhythmias and better clarify the importance of 
triggers (i.e. transient myocardial ischemia), on a predisposing myocardial 
background (i.e. diffuse myocardial fibrosis), in arrhythmogenesis. Finally, a 
prospective registry, aiming at scanning cardiac arrest survivors more than once 
during their follow-up, may help distinguish early and late predictors of recurrent 
events and further help in the difficult stratification of arrhythmic risk in this 
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